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Business Coalition Development:
Inlpact on Public Policy and Legislation

Executive Summary
My responsibilities as an intern with Pfizer, Inc. 's Michigan Office of State Government
Relations focused on the development of public policy partnerships with numerous
organizations including voluntary health associations and senior centers throughout the
state of Michigan beginning January 1, 2002 and continuing until April 19, 2002.
Initially, I met ,vith representatives of these groups and others, such as the NAACP and
AARP, in order to raise the public's awareness of problematic changes to the
phamlaceutical benefits provided by the state of Michigan to Medicaid 'fee-for-serv'ice'
recipients and the beneficiaries of other state sponsored health care programs. For this
purpose, I organized an infoffi1ational meeting at which the attendees \vere informed of
the adverse changes to Medicaid and the Elder Prescription Insurance Coverage
programs, followed by a presentation on the innovative Pfizer Share Card, which extends
pr~scription assistance to seniors who are enrolled in Medicare, lack a prescription dnlg
benefit and meet specified income guidelines. I subsequently authored regular
communication updates for the meeting attendees on .tvfedicaid and Medicare related
issues, as I continued to nieet with additional patient advocacy groups. I \vas charged
v'lith the responsibility of extending invitations to serve on the Board of Directors for the
newly incorporated Senior Citizens for Prescription Drug Fairness to representatives of
the Visiting Physician's Association, NAACP, Epilepsy Foundation, IVrichigan
Association of Senior Cent~rs and Health Care Partners) and comnlunication was
facilitated through meetings, conference calls and en1ail.
As changes to the prior authorization program that adversely affected many Ivfedicaid
recipients were implemented by the state of rv1ichigan, a campaign strategy to defeat th~
initiative was developed, and I served as an information resource both internally and for
the coalition members and various consulting firms. The campaign evolved into a
support strategy for alternative legislation providing the state of iVlichigan \vith a ne"v
revenue source through the extension of Medicaid "best price" rebates to all state run
health care programs by pharmaceutical manufacturers. The menlDers of the coalition
consequently becan1e lead contacts in informational breakfasts and luncheons \vith key
rnembers of the House Appropriations committee.
Throughout my internship at Pfizer, I have learned that relationships between
organizations vvith comnlon interests are invaluable~ and by leveraging such synergies,
public policy can ultill1ately be influenced. The collaborative efforts of organizations
involved with the campaign against prior authorization are currently being capitalized
upon, and through this coalition, the changes implemented by the state of Michigan could
be reversed and/or modified through legislation. My employrnent with Pfizer, Inc. has
provided exposure to the reality of corporate initiatives with respect to influencing public
policy through legislation. This experience has allowed my to complete numerous
challenging tasks while enhancing various skills and abilities.

College Scholars Senior Project Preliminary Report
Hannah M. Kiser
January 9, 2002
The purpose of this communication is to infonn you of my responsibilities and activities
to date in my internship with Pfizer, Inc. All infonnation transmitted is considered
proprietary and confidential.

Background:
The State of Michigan is currently experiencing a fiscal crisis, as are many other states.
In response to the current conditions of the state's finances, certain changes to progran1s
have been proposed. The Michigan Department of Community Health has proposed a
much more restricted fonnulary for those recipients of the Elder Prescription Insurance
Coverage program as well as those Medicaid recipients who are in the "fee for service"
category.
Under the current programs, doctors simply prescribe the drug that best suits the patient's
need. In an effort to resolve a shortfall in the state Medicaid budget, physicians will now
be required by law to obtain what is referred to as "prior authorization" before prescribing
any drug not listed on the unrestricted Medicaid fonnulary. In order to obtain prior
authorization, the physician must place a call to and receive approval from First Health, a
phannacy benefit manager in Virginia, a process estimated to take ten minutes per
prescription on average. Due to the extremely limited unrestricted Medicaid fonnulary,
many drugs now commonly prescribed to patients, such as Celebrex, Lipitor, Geodon,
Zoloft, and Aricept, are to be placed on prior authorization. This will most likely result in
the patient being switched from a drug they are currently taking to another, possibly less
effective treatment with an increased number of side effects. It is also expected that some
physicians will discontinue the treatment of Medicaid and EPIC recipients due to the
undue burden that this procedure places on them.
It is imperative for those individuals who will be affected by these changes in
phannaceutical availability to be aware of these developments, and the assistance of
Voluntary Health Associations is being requested in order to ensure that this is carried out
in the most efficient and effective manner. The best interests of patients and adequate
patient care can best be protected through collaboration in order to communicate the
ilnpact of this policy on Michigan's most vulnerable citizens, the less fortunate and the
elderly. The damage to patient care and physician participation promises to be
monumental without the response of those who stand to lose the most.

The Phannaceutical Research and Manufacturer's of America (PhRMA) sued the state of
Michigan on the grounds that the process by which the prior authorization process was
implemented was unconstitutional. Several Mental Health advocacy groups have also
filed suit in this case due to the irreparable hann that this program would cause their
consti tuen ts.

Developments:

On Monday, January 7, 2002, a hearing was held on the motion for preliminary
injunction brought by PhRMA. The judge ruled in favor of the phalmaceutical and
mental health plaintiffs and issued an injunction. The Attorney General's motion for stay
pending appeal was denied, and the language of the order for injunctive relief is currently
being worked out between the opposing sides. The Attorney General is expected to file
an emergency appeal in the near future.
Responsibilities:

My role in the Michigan Medicaid fonnulary response is that of a liaison between the
voluntary health organizations of the state and Pfizer. Over the past week, in addition to
becoming familiar with the fonnulary issue, I have contacted approximately 28 VHA's to
schedule briefings on this issue. Briefing materials for these meetings have been drafted
and submitted for approval.
I began meeting with these groups on Tuesday, January 8, 2002 and have completed
appointments in the Lansing and Metro-Detroit areas. The response from the associations
has varied depending on the level that their particular patient bases are affected by the
fonnulary changes.
Expectations:

If the committee deems it appropriate, I will report on a weekly basis throughout the
duration of the internship and in person when possible. The internship is expected to last
for sixteen weeks ending on April 19, 2002.
Committee Members and Contact Information:
Dr. Harold Black (Chair)
Phone: 974-1721
Email: hblack@utk.edu
Fax: 974-1715
Email: dtandy@utk.edu
Dr. David Tandy
Phone: 974-7705
Fax: 974-7173
Email: rcunning@utk.edu
Dr. Bob Cunningham
Phone: 974-7050
Contact Information:
Hannah Kiser
Pfizer, Office of State Government Relations
209 North Walnut, Suite C
Lansing, MI 48933
(517) 485-8301
Email: hannah.kiser@pfizer.com
hmkiser@utk.edu

TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: January 21, 2002
RE: College Scholars Senior Project Report

Report
Over the past week, I have contacted forty-one voluntary health agencies, as well as the NAACP
and AARP, in order to set up briefing appointments on the proposed changes to the Medicaid
and Elder Prescription Insurance Coverage program [EPIC] formulanes in Michigan.
response from the associations has varied; however, most have been very receptive.

The
Some

agencIes have already taken a proactive approach to ensure quality patient care for their
constituencies by infoffi1ing government representatives and local media of the eminent adverse
impact on Medicaid recipients and plan to continue to increase awareness among their
popUlations. Still others are cognizant of the policy directive, but have not yet taken a position.
A small minority of organizations has determined that they would be relatively unaffected by the
possible change in policy and thus, are not planning to address the issue. This communication
contains a synopsis of the ten group meetings that have taken place thus far in Detroit, Lansing
and Kalamazoo.

In meeting with the American Cancer Society, the Director of State Government Relations made
me aware of Michigan Partners for Patient Advocacy group. This loose coalition of voluntary
health organizations aims to ensure and protect the quality of patient care in Michigan and has
kept member groups, of which there are approximately 60, informed of the developments with
respect to the proposed changes. This group requires consensus in order to take a collective
stance on any given issue, but has authorized any member organization to react to the policy, as
they deem appropriate.

The Mental Health Association has already responded by filing

a~

an intervenor in the

Phannaceutical Research and Manufacturers of America v. Michigan Department of Community
Health lawsuit. This group would be impacted, arguably more than any other would due to the
specific nature of mental health drugs. The affidavits filed by two mental health patients indicate
that any change to the treatment regimen they are now utilizing would be disastrous due to a
decrease in the quality of life they now experience. The restrictive forn1ulary advocated by the
Michigan Department of Community Health would equate to catastrophe for these Medicaid
recipients.

The Chronic Illness Awareness Coalition, although unable to lobby collectively, is aware of the
issue at hand, and will communicate to member organizations that infonnation on the forn1ulary
can be obtained from the Pfizer Office of State Government Relations. The Director of the
Coalition is directly affected by this policy and provided a copy of their directory for further
assistance. Although the Department of Community Health has indicated that any drugs not
listed on the proposed changes list will be available without restriction, she is wary of these
promises and wants to be kept up to date on all developments.

Paralyzed Veterans of America are not directly affected by the policy changes due to the fact that
most of their population has military health benefits. They have, however, proved an invaluable
resource by recommending other disability groups who have significant Medicaid recipient
populations. I also participated in a briefing of the Michigan Association of Centers for
Independent Living in order to make the disability agencies present aware of the situation and
put them in contact with Pfizer.

The American Lung Association indicated that some physicians have voiced concern over the
lack of choice in asthma treatments. They have not been proactive in advocating a position, but
would be interested in meeting with other voluntary health agencies to discuss the problem and
assist in suggesting solutions.

The Director would also like to be kept abreast of any

developments.
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The Huntington's Disease Society was familiar with the Medicaid problem due to their
participation in the Michigan Partners for Patient Advocacy.

Personal experience with the

disease led the President of the Society to be strongly opposed to the prior authorization process.
Those suffering from Huntington's disease must have access to different medications as soon as
possible due to the dynamic nature of this ailment, and the drug that may have worked in the past
can become ineffective without warning. This group can be expected to be active in combating
the prior authorization process.

The Leukemia Society of America was extremely involved in the initial reaction to the proposed
changes and was very receptive to initiating a grassroots campaign effort. They provided a list
of their most utilized medications and requested notification of the status of each, as well as,
referrals to social workers and Gilda's Club, a non-profit home for individuals being treated for
leukemia who are unable to afford overnight accommodations in the metro-Detroit area. The
President is also going to brief the contact person on the West side of the state.

The Epilepsy Foundation of America activated their grassroots network in the initial fight against
the formulary changes and is willing to do so again. Epilepsy drugs arl similar to those in the
mental health category in the sense that the treatment is very individual specific. Dilantin, one of
the best in class anti-epileptic prescription drugs, is on prior authorization, which would without
a doubt prove detrimental to the treatment of epileptics on Medicaid or the Elder Prescription
Insurance Coverage program.

While seizures can often be treated by other means, these

alternative prescriptions may not prevent them as well as Dilantin does.

This group was

interested in the possibility of an open forum for agencies opposed to the restrictive formulary
and offered to help with the organization of such an effort.

The American Liver Foundation was unaware of the proposed changes to the formulary, and
while not affected quite as heavily as the other organizations, was not opposed publicizing the
Issue. The group was encouraged to promote letter writing by those who would be affected.

The Alzheimer's Association understood the magnitude of the issue and is willing to engage in a
letter writing campaign. The most well-known prescription medication for Alzheimer's did not
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require prior authorization; however, Aricept and another treatment are restricted. As was the
case with nlental health and epileptic medications, these treatments are very patient-specific, and
restrictions as to necessary treatment would have an extremely negative effect on those suffering
from this disease.

In addition, a meeting with the Michigan Association of Senior Centers has taken place and
further contact and interaction with this pivotal group is anticipated. The Elder Prescription
Insurance Coverage program is reported to have had minor glitches in coverage, but it is
expected that prior authorization could completely incapacitate the program's ability to serve
seniors effectively.
Summary
It is apparent that the voluntary health agencies are opposed to the implementation of a restricted

formulary for Medicaid patients. Many of those whom I met with indicated that they understand
the importance of fiscal responsibility, but were strongly opposed to the act of "balancing the
budget on the backs of the most needy citizens." These individuals have more than enough
difficulty accessing the health care system without the additional burden of this policy. There is
also evidence that indicates that decreasing prescription coverage leads to increases in
hospitalization and nursing home costs to the state.

[See Print Media] To decrease

pharmaceutical offerings would upset the delicate equilibrium of Medicaid fee for service
recipients statewide, which constitutes irreparable harm as the Ingham County district court
judge so clearly elucidated at the preliminary injunction hearing.

Developments

A three-judge panel of the Michigan Court of Appeals has ruled that the stay issued by the
Ingham County district court is to be reconsidered after a hearing on the merits of the case.
While this was not the ideal tum of events for the pharmaceutical companies or the patient
advocacy groups, the outcome could go either way at the appeals level.

Meanwhile, Pfizer is prepanng the sales force to deal with this issue by formulating the
necessary forms to obtain prior authorization from the pharmacy benefit manager, should this
process be implemented.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: January 28, 2002
RE: College Scholars Senior Project Report

Report

I have continued to contact voluntary health associations and other groups with a vested interest
in the Michigan Medicaid issue. In addition, the Manager of Pfizer Civic Affairs, an office
within the Corporate Affairs division located at corporate headquarters, was brought in for the
purpose of giving me additional training in the method of mobilizing patient advocacy groups.
Her insight was especially helpful, and I was able to learn several new techniques for engaging
individuals who manage voluntary health associations. This process, which is more commonly
referred to as alliance development, is an area of expertise that is currently under development;
Pfizer has implemented this strategy on a national level over the past few years. Other groups
such as the Pharmaceutical Research and Manufacturer's of America are also following this
strategy as means of stimulating organizations to respond to issues which adversely affect them.
The following is a brief synopsis of the meetings that I have had in the past week.

The American Heart Association is a part of Michigan Partners for Patient Advocacy. This
group has experienced major cuts in state program funds and is looking for innovative ways to
partner with other organizations in order to continue their assistance of those with heart disease
and other heart-related conditions. They have been in contact with the s.lles force, but have yet
to enact any programs.

They have formed a coalition with the American College of

Cardiologists on the state level, and this effort resulted in written statement expressing the
College's displeasure with the proposed formulary changes. Although not affected greatly by the
change to the Medicaid formulary, the group is concerned due to implementation of these same
limitations on the EPIC program (Elder Prescription Insurance Coverage).

The Heart

Association seemed open to the possibility of being a more vocal advocate of patients' rights as a
result of the EPIC changes.

The legislative director of the Arthritis Foundation informed me of their legislative priority to
educate legislators as to the threat of arthritis at any age.

The organization is currently

developing a patient advocacy program which is intended to train individuals suffering from
arthritis to speak with their legislator with the hopes of increasing funding for arthritis treatment
and cure research. The director intends to attend the forum for voluntary health associations and
senior centers, and she was in agreement about imminent adverse impact on patient care in the
state.

This group partnered with the Michigan Department of Community Health on a

publication entitled the "Michigan Arthritis Action Plan," but the extent to which they are
involved with the Department has yet to be determined.

American Autoimmune Related Diseases is an organization with a federally focused agenda.
Recently, they were influential in advocating a $420 million dollar legislative program within the
Children's Health Act, which is designed to further Autoimmune disease research.

Federal

issues of this magnitude coupled with the rather small staff make it difficult for the group to be
heavily involved in state issues.

The organization has however, signed onto a statement

opposing the proposed changes to the Medicaid and EPIC formularies, and they are also open to
informing their popUlation of the policy through direct n1ail. The director will be unable to
attend the meeting, but would be interested in hearing the outcome.

In addition to these meetings, I have assisted with the preparation of a PowerPoint presentation
summarizing the issues Pfizer is facing in Michigan for presentation to a national audience. [See
attached.] This presentation explains the process of prior authorization, as well as, the effect that
such a policy could have on the company's profit margin. The implications of this policy are not
limited to the state of Michigan, as other states could follow this directive if implemented, which
would result in a blow to the research and development industry. Without the input of those who
stand to lose the most, any attempts made to defeat this policy by a pharmaceutical firm will be
viewed as self-serving. Therefore, the input of all affected by this policy is imperative to a
successful rebuttal of the proposed changes, and those in political office must be aware of the
political magnitude of this decision.
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Summary

The groups I have met with have all been in agreement that the proposed policy has a negative
impact on patient care. Most of the groups are very concerned and have already been involved in
a public response and are interested in a collaborative effort to prevent this from going into
effect. It has been a learning experience to work with so many different individuals with such
varied degrees of expertise and unique approaches. The job of developing relationships with
such interesting people has been exciting, and I look forward to continuing to meet and interact
with a variety of personalities marked by unique senses of purpose.

Developments

Pfizer also announced the Pfizer Share Card which allows Medicare recipients to purchase Pfizer
prescriptions at the cost of $15 per 30 day supply upon meeting minimal income qualifications.
The program has no limits and is targeted at the 7 million Medicare recipients who currently
have no prescription coverage. The voluntary health associations are pleased to hear that Pfizer
is taking a stand and providing much needed assistance to this group of people.

As suggested by the senior campaign consultant, a meeting of all voluntary health associations
who wish to participate has been scheduled for February 5, 2002. This meeting will allow those
groups who have not yet been briefed regarding this issue to be brought up to speed, as well as
refresh those organizations that are aware of the current situation. The goal of the meeting is to
promote a collaborative effort between these organizations so that legislators and other public
officials will become aware of the negative impact of this restrictive policy.

The changes to the Medicaid pharmaceutical policy are scheduled to take effect on February 1,
2002; however, there are indications that the pharmacy benefit manager may be unprepared to
begin the provision of the services necessary to run the program. The Pharmaceutical Research
and Manufacturer's lawsuit is still to be heard at the Court of Appeals, at which time the
constitutionality of the policy will be determined.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: February 4, 2002
RE: College Scholars Senior Project Report
Report

Over the past week, I have primarily focused on preparing for the meeting of voluntary
health associations and senior centers, which will take place on Tuesday, February 5,
2002. The goal of this nleeting is to brief the associations on the Pfizer Share Card and
inform them of the changes to the Medicaid formulary . We hope to then gather feedback
on ways that the groups can collaborate in order to change the proposed policy through
grassroots advocacy. At the present time, we expect approximately 15 voluntary health
associations to be represented, in addition to a number of senior center representatives.

In addition, I also met with the president of the Immune Deficiency Foundation of
Michigan. Their population has a large number of Medicaid recipients, and they were
very concerned with the changes, which were to be effective on February 1, 2002. The
group has an interesting history of grassroots advocacy on a national level, as they
recently battled Disney on the release of a movie entitled "Bubble Boy," which depicted
a child with immune deficiency disorder in what was considered a romantic comedy.
The group, although unsuccessful in preventing the release of the film, strove to educate
the public about the gravity of the disease. While they have not yet been involved with
the issue of the Medicaid formulary and are required to submit such proposals to their
national affiliate prior to taking action, they were extremely open to weighing in on the
issue due to the negative impact on their constituency.

One of the voluntary health association leaders with whom I had previously met
contacted me early on the morning of February 1, 2002 to inform me that she had
received a letter notifying her of the changes to Medicaid offerings on January 31. The

letter from the Director of Medicaid was dated "January 2002" and vaguely indicated that
there would be changes to Medicaid pharmaceutical benefits in order to ensure the
ongoing provision of coverage by the state. She indicated that had we not met to discuss
the issue, she would not have realized the extent of the changes in pharmaceutical
availability or the new procedural requirements. She voiced grave concern for Medicaid
recipients, of which there are estimated to be 350,000 to 400,000 in the Medicaid "feefor-service" population, due to the vague nature and poor timing of the letter. I was able
to provide her with contact information for her state legislators, as well as the chairs of
the Community Health subcommittee chairs in the Senate and House, so that she could
voice her displeasure with the policy changes and the unacceptable manner in which the
recipients were notified. She was very clear in articulating her concern that this policy
change could have life and death implications for recipients in her organization's
population.

I am looking forward to the meeting of the voluntary health associations, because there
has not yet been an organized open forum for the communication of specific concerns
about this policy initiative. Due to the circumvention of the legislative process in the
implementation of this policy, public response on the issue was never considered, and the
changes were never submitted to the legislature as a whole. The individuals planning to
attend include mental health advocates, AIDS representatives, as well as representatives
organizations such as the Epilepsy Foundation, who represent segments of the population
impacted significantly by changes in the availability of prescriptive treatments.

Summary

Up to this point, I have contacted approximately sixty voluntary health organizations in
order to notify them of the changes to the formulary. Some have already weighed in on
this issue, and those I have met with have voiced serious concerns regarding the effect
this change will most likely have on the Medicaid and other affected popUlations. The
inefficiency of the Medicaid agency has been alarming, and when questioned Friday on
the schedule of implementation for the formulary changes, one Medicaid employee
confessed, "It's just one big mess."

It is unfortunate that the state has chosen to
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haphazardly enact changes at the expense of Medicaid recipients, and it seems that the
Medicaid agency is only beginning to comprehend the "mess" that has been created.

Developments
The formulary was scheduled to go into effect on Friday, February 1, but it seems that the
Department of Community Health is not prepared to implement the proposed changes. In
print media, one spokesperson for the Department of Community Health reported that the
formulary changes would be effective as of February 1, but would not be enforced "for a
few weeks". In fact, changes to the list of drugs requiring prior authorization were
evident on the morning of February 1, when Lipitor and possibly others were
unexpectedly changed to unrestricted status. It is apparent that the policy changes were
not thoughtfully considered, and now that the time has come to in1plement the proposal,
neither the State nor the pharmacy benefit manager is prepared to enforce the changes.

There is also a meeting scheduled for Monday, February 4, which will allow consumer
advocates and providers to voice input on the Governor's expansion of Medicaid
coverage to an additional 200,000 recipients through a broad waiver. The groups will be
asked to comment on the eligibility, benefits and budgeting aspects of the expansion
proposal. Several of the advocates with whom I have networked are planning to attend
because they are concerned that the expansion will be employed at the expense of the
existing beneficiaries, namely their constituents.

Also included with this report are materials prepared for the meeting of voluntary health
organizations and senior centers to be held on Tuesday, February 5, 2002 such as
Medicaid Health Alert and form letters directed toward legislative officials.
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[Date]
The Honorable [Full Name]
State Representative
State Capitol
P.O. Box 30014
Lansing, MI 48909-7514
Dear Representative [Last Name]:
I am writing to inform you of my objections to the proposed changes in the Elder Prescription
Insurance Coverage program.
This program was established to "enhance access" to
pharmaceutical medications for low-income senior citizens of the state of Michigan. The
proposed changes to the program will not only restrict access to prescription medication, but
could also prompt physicians to discontinue the treatment of EPIC recipients due to the undue
bureaucratic burden placed on them through the prior authorization requirements and restricted
formulary.
The physician should be the one to determine the best treatment for the patient if adequate
patient care is to be achieved, and heightened prior authorization requirements will not only
circumvent physician expertise but also simultaneously erode patient care. A healthcare
operative in Virginia is not properly equipped to determine the appropriate prescription for the
Michigan citizen.
The EPIC program is in place for the purpose of helping the senior citizens of Michigan with life
sustaining prescription costs, and I assert that if seniors are forced to discontinue the use of
medications which have currently stabilized their conditions and switch to other forms of
treatment which may be less effective and cause additional side effects, the result will be
disastrous. This group of citizens has contributed to the state of Michigan over the years, and it
is an outrage to decrease the prescription benefits provided to these individuals.

*[I am currently taking
, which is expected to be placed on prior authorization if
the changes to EPIC are implemented.] I am very concerned for my own well being and the well
being of the seniors of Michigan; I urge you to do whatever is necessary to ensure that these
changes are reconsidered in a manner that would be advantageous for the seniors of Michigan.
Sincerely,

[Your Name & Address]

[Date]
The Honorable [Full Name]
State Representative
State Capitol
P.O. Box 30014
Lansing. MI 48909-7514
Dear Representative [Last Name]:
I am writing to express my strong opposItIon to the implementation of increased prior
authorization procedures in Michigan's Medicaid and Elder Prescription Insurance Coverage
(EPIC) programs. It is wrong to remedy budget shortfalls by making appropriate treatments less
accessible to Michigan's most vulnerable citizens, the less fortunate and the elderly.
Furthermore, this process strips the physician of the ability to prescribe the most appropriate
medication by limiting access through a restricted formulary or alternately, requiring approval
from an out of state pharmacy benefit manager with no knowledge of the patient's needs.
The Michigan Department of Community Health's mission statement reads as follows:
1. to promote access to the broadest possible range of quality services and supports
2. to take steps to prevent disease, promote wellness and improve the quality of life
3. to strive for the delivery of those services and supports in a fiscally prudent manner
Clearly, the limitation of pharmaceutical availability through prior authorization requirements
and a restricted formulary directly oppose the goal of promoting access to the broadest range of
quality services and supports, while forcing patients currently stabilized on medications to alter
their treatment contradicts the promotion of wellness and the improvement of the quality of life.
It is therefore impossible to deliver the aforementioned services and supports, defeating the goal
of doing so in a fiscally prudent manner. Increases in prior authorization requirements and
restricted formularies are clearly contradictory to the mission of the Michigan Department of
Community Health.
It is the duty of elected representatives to uphold the principles of equality and democracy by

ensuring that the well being of their constituency is protected. The proposed changes to the
Medicaid/EPIC formulary violate the very purpose of the Michigan Department of Community
Health and in doing so, endanger the well being of the MedicaidlEPIC recipients. It is my hope
that you will hold the Michigan Department of Community Health to its mission by ensuring that
the proposed changes are reconsidered, and thereby protect the well being of the citizens of the
state of Michigan.
Sincerely,

[Your Name & Address]

[Date]
The Honorable [Full Name]
State Senator
State Capitol
P.O. Box 30036
Lansing, MI 48909-7536
Dear Senator [Last Name]:
I am writing to inform you of my objections to the proposed changes in the Elder Prescription
Insurance Coverage program.
This program was established to "enhance access" to
pharmaceutical medications for low-income senior citizens of the state of Michigan. The
proposed changes to the program will not only restrict access to prescription medication, but
could also prompt physicians to discontinue the treatment of EPIC recipients due to the undue
bureaucratic burden placed on them through the prior authorization requirements and restricted
formulary.
The physician should be the one to determine the best treatment for the patient if adequate
patient care is to be achieved, and heightened prior authorization requirements will not only
circumvent physician expertise but also simultaneously erode patient care. A healthcare
operative in Virginia is not properly equipped to determine the appropriate prescription for the
Michigan citizen.
The EPIC program is in place for the purpose of helping the senior citizens of Michigan with life
sustaining prescription costs, and I assert that if seniors are forced to discontinue the use of
medications which have currently stabilized their conditions and switch to other forms of
treatment which may be less effective and cause additional side effects, the result will be
disastrous. This group of citizens has contributed to the state of Michigan over the years, and it
is an outrage to decrease the prescription benefits provided to these individuals.
*[1 am currently taking
, which is expected to be placed on prior authorization if
the changes to EPIC are implemented.] I am very concerned for my own well being and the well
being of the seniors of Michigan; I urge you to do whatever is necessary to ensure that these
changes are reconsidered in a manner that would be advantageous for the seniors of Michigan.
Sincerely,

[Your Name & Address]

[Date]

The Honorable [Full Name]
State Senator
State Capitol
P.O. Box 30036
Lansing. MI 48909-7536
Dear Senator [Last Name]:
I am writing to express my strong opposItIon to the implementation of increased prior
authorization procedures in Michigan's Medicaid and Elder Prescription Insurance Coverage
(EPIC) programs. It is wrong to remedy budget shortfalls by making appropriate treatments less
accessible to Michigan's most vulnerable citizens, the less fortunate and the elderly.
Furthermore, this process strips the physician of the ability to prescribe the most appropriate
medication by limiting access through a restricted formulary or alternately, requiring approval
from an out of state pharmacy benefit manager with no knowledge of the patient's needs.
The Michigan Department of Community Health's mission statement reads as follows:
1. to promote access to the broadest possible range of quality services and supports
2. to take steps to prevent disease, promote wellness and improve the quality of life
3. to strive for the delivery of those services and supports in a fiscally prudent manner
Clearly, the limitation of pharmaceutical availability through prior authorization requirements
and a restricted formulary directly oppose the goal of promoting access to the broadest range of
quality services and supports, while forcing patients currently stabilized on medications to alter
their treatment contradicts the promotion of wellness and the improvement of the quality of life.
It is therefore impossible to deliver the aforementioned services and supports, defeating the goal
of doing so in a fiscally prudent manner. Increases in prior authorization requirements and
restricted formularies are clearly contradictory to the mission of the Michigan Department of
Community Health.
It is the duty of elected representatives to uphold the principles of equality and democracy by

ensuring that the well being of their constituency is protected. The proposed changes to the
MedicaidlEPIC formulary violate the very purpose of the Michigan Department of Community
Health and in doing so, endanger the well being of the MedicaidlEPIC recipients. It is my hope
that you will hold the Michigan Department of Community Health to its mission by ensuring that
the proposed changes are reconsidered, and thereby protect the well being of the citizens of the
state of Michigan.
Sincerely,

[Your Name & Address]

OPTIONAL PARAGRAPHS
According to the Michigan Constitution, public health and the general welfare of the people of the state of
Michigan are matters of primary public concern. As a concerned citizen of this state, it is my finn belief
that the practice of denying appropriate care to Medicaid recipients through pharmaceutical fonnulary
limitations and prior authorization requirements is unacceptable. It is clear that the creators of the
proposal for Medicaid reform have chosen to balance a budget at the expense of the individuals in the
most critical need of proper medical attention, while the importance of public good has been lost and the
focus has been shifted instead to the bottom line. While fiscal responsibility is of the utmost importance,
this priority should not preempt the provision for those individuals least able to access proper medical
attention as is so adequately stated by the Constitution of this state. The shortfall in the Medicaid budget
should certainly be addressed and remedied, but not at the expense of Michigan's most vulnerable
citizens.
While a committee may be able to determine the least costly drugs in each class, the "best in class" title
chosen for such Medicaid prescription medication is certainly far from accurate. The fonnulary drugs
were not chosen with regard to effectiveness or efficiency, two of the criteria the Michigan Department of
Community Health purports to adhere to in their health care delivery policy. Regardless of the extensity
of the research behind such classifications, it cannot replace a physician's expertise. When given a choice
between an unbiased physician analysis and a restricted prescription detennined by a committee that the
patient has never met, the physician's analysis would undoubtedly be preferred. In fact, if the committee
members responsible for the "best in class" drug list were subject to this limited formulary, they might be
more likely to expand the offerings provided to Medicaid beneficiaries. The poor and elderly should not
suffer merely because it is the most convenient way to solve budget shortfalls.
The quality of patient care for Medicaid recipients is in jeopardy if the proposed changes to the Medicaid
phannaceutical offerings are not more closely examined and revised. The list of drugs requiring prior
authorization is copious, and one can only imagine the effect of switching a patient from an effective,
slightly more expensive medication to a less expensive, less effective prescription with additional side
effects. For those taking a number of prescription medications, this process could be catastrophic and the
damage irreparable. The trauma for Medicaid recipients could be completely avoided, however, if the
Michigan Department of Community Health remained cognizant of the agency's goal, which aims to
"design and implement a service delivery system ... that is accessible, efficient, effective and innovative."
A restricted fonnulary and severely diminished access to phannaceuticals through prior authorization
meets neither of these criteria and in fact, is contradictory to the aforementioned goal of the agency.
Patient care should be the utmost priority for the Department of Community Health as the agency so aptly
states, however, the current proposal is lacking and should therefore be revised.
Mental health may be one of the most sensitive aspects of managed health care. Due to the fact that
numerous attempts to find a successful treatment are often necessary and compliance with the successful
regimen is essential, the current modifications to the Medicaid formulary will likely result in grave
damage to the mental health care of Medicaid and EPIC recipients. Not only will the doctors be limited
to a restricted number of approved prescription options, but the will also be subject to prior authorization
requirements should they deem a restricted phannaceutical the most appropriate choice for their patient.
These patients' needs are no less important than those who can afford to pay top dollar for mental health
care, and these individuals should not be forced to carry the burden of balancing a Medicaid budget
shortfall. Rather, the Michigan Department of Community Health should reconstruct a plan more
sensitive to the needs of some of Michigan's most vulnerable and at-risk citizens.

TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: February 11,2002
RE: College Scholars Senior Project Report
Report
On Tuesday, February 5, 2002, representatives from fifteen voluntary health associations and thirty
senior centers came together at the first coalition meeting to discuss the changes to the Michigan
Medicaid and EPIC formularies and the effect these changes will have on their respective
populations. The meeting opened with frank input from the meeting participants regarding the
positive aspects, as well as the shortcomings, of the current Medicaid and EPIC programs. Many of
the individuals employed at the senior centers deal with EPIC patients on a daily basis as they assist
enrollees with the application procedure. The voluntary health association representatives, which
included an HIV/AIDS advocate, Epilepsy Foundation staff, Lupus Foundation Director and home
care registered nurses, among others, are in contact with recipients of the Medicaid "fee-forservice" recipients and are consequently able to assess the likely impact of changes to benefits on
this constituency. The changes to the EPIC program evoked frustration and even anger from a
number of senior center representatives who have enrolled individuals believing that it would
provide access to the necessary pharmaceuticals for seniors who had no other prescription coverage.
These senior center representatives voiced concern that those seniors who are currently stabilized on
treatments, which will require prior authorization under the changes to be enforced on February 11,
2002, will be adversely affected by the policy.

After questions were fielded on the Medicaid issue, I gave a presentation on the Pfizer Share Card
program. [See attached.] The group was extremely interested in this new approach to senior
assistance and seemed excited to be able to offer such a reachable option to those seniors who
qualify.

In total, over 3200 requests for Share Card brochures were turned in, indicating the

overwhelmingly positive response to this innovative initiative.

Over lunch, meeting attendees

commented that other pharmaceutical companies should consider implementing comparable
programs. Several senior centers requested that a representative of our staff present the program to

that a representative of our staff present the program to their respective senior centers. The meeting
concluded by answering any remaining questions from the audience.

I met with the governmental relations representative of the AARP to discuss the Medicaid issue,
and this meeting turned out to be surprisingly advantageous. The organization generally advocates
preferred prescription medication lists and fonnularies, believing that such practices place
"downward pressure" on phannaceutical prices. While the representative did acknowledge that
prescription medicine can lower hospital and nursing home care costs, they asserted that policies
encouraging the use of generics are of benefit due to their belief that it causes a decrease in the price
of brand name drugs. When it was pointed out that Pfizer does not dispute the use of generic
medications, but brand name drugs are sometimes more appropriate treatments, they did not
disagree but were not swayed in their mindset.

Their representative also reported that they were planning to file an amicus curiae brief on behalf of
the state of Michigan on this particular issue. Anticipating that seniors would perceive AARP as
being in favor of phannaceutical restrictions, he also indicated that the group was planning to
produce a brochure directing seniors to their phannaceutical company to inquire as to why the
company had not provided the requested rebates to the state. He also suggested that our corporate
headquarters contact their national office, so that the state offices would have the authority to refer
inquiries to the Share Card 800 number, despite the supportive press release of the national office
on the Share Card. This infonnation was of note to Pfizer, NY, and subsequently another vocal
senior group has been contacted for their input on the changes to the Medicaid and EPIC program.

After these developments, I have followed up with the groups present at the meeting, while also
trying to schedule appointments with those who were not able to attend. The groups present have
been very complimentary and are excited about the Share Card. It will be more of a challenge to
see that they follow through with contacting their legislative officials on the subject of the changes
to Medicaid and EPIC. A follow-up email was sent to the attendees, while contact is also being
made by phone as well.
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Summary

The meeting of the health associations and senior centers was a success in that it provided a forum
for groups to come together and discuss the current policy, as well as, comment on the negative
aspects of the changes. Representatives have indicated to me that it was beneficial for them to
interact with their contemporaries and discuss possible solutions to current situations. Meeting with
AARP provided me with valuable information that allowed Pfizer to take a proactive approach to
their alliance with the state on this issue.

Developments

The sales force has stal1ed to relay horror stories from physician's offices frustrated by the increase
in red tape. One office reported being put on hold for over twenty minutes in an attempt to get prior
authorization for a single prescription, only to be denied and then directed to the emergency
number, where the staff member was put on hold for another fifteen minutes. After explaining the
medical necessity of the prescription due to the patient's aggressive behavior, the request was
finally approved. This is just one instance that has been reported, and it is anticipated that this will
be the rule rather than the exception. When our office asked for a copy of the Medicaid and EPIC
prior authorization forms on Wednesday, February 6, 2002, the pharmacy benefit manager
representatives were less than equipped to answer questions, but finally provided our office with the
necessary documents. Meanwhile, members of the sales force are trying to come up with ways to
assist physicians and their staffs in the onerous process of receiving prior authorization.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
RE:

College Scholar Senior Project Report

DATE: February 18, 2002
Report

Following up with the individuals who attended the February 5 meeting has been an
involved process. In addition to informing them that we will be able to send the Pfizer
Share Card enrollment kit, I have also been inquiring as to whether or not they have been
in contact with any legislative officials with respect to the changes to the Michigan
Medicaid formulary. Most are waiting to contact their officials until they have personal
interaction with an individual who has difficulty accessing their prescription medication
due to the prior authorization policy, however, the Department of Community Health
recently issued a letter stating that February 1-8 was a designated "testing period" and
that the prior authorization system would not be implemented until "at least February
25." The Department then plans to phase in drug classes on a specified schedule, the first
to be affected being the antianxiety, antihistamines, glucocorticoids and macrolides.

I have updated those who attended the coalition meeting of the Department's
announcements, as well as the position of AARP on this issue. The response to the
AARP amicus brief has been surprising. One senior center representative who is also in
charge of the local AARP chapter was shocked at the organization's position and
contacted the AARP State Government Affairs Representative, with whom I had
previously met to discuss the issue of the changes to Medicaid prescription benefit. She
intends to advise neighboring AARP chapters of the position taken by the state office and
was incensed that there was no chance for local chapters to offer input.

The Visiting Physician's Association has begun compiling data on the amount time
devoted by the staff to prior authorization requests and the outcome of such requests.

Their representative reported that the care coordinators, whose job it is to submit prior
authorization requests, are extremely frustrated and would have the data together by the
end of the week to be sent electronically.

The Leukemia and Lymphoma Society Patient Services Representative who attended the
Michigan Health Alert coalition meeting indicated that the Medicaid issue was of
importance to their population, however, the state branches are not permitted to act
without the approval of the national office on any given issue. She referred me to the
organization's Government Relations spokepersons in Washington, D.C., and through
Pfizer's Civic Affairs office in New York contact was made. The Government Relations
spokesperson was extremely pleased to hear that members on the state level were
interested in patient advocacy initiatives and approved mobilization of the patient
advocacy base in Michigan.

In addition, I have drafted language for the contracts to be submitted to the consulting
firms whose services are to be employed in the campaign against prior authorization.
These contracts will include deliverables and payment schedules, as well as a complete
listing of expectations specific to each firm.

On behalf of Pfizer, Inc., I attended the Michigan League of Conservation Voters
Legislative Awards Breakfast, where four state legislators were honored for their
exemplary commitment to environmental issues, such as proposing a process to develop a
set of land use planning goals to guide state investments and effecting strategies to
contain invasive species and mitigate their impact on the Great Lakes.

One of the

representatives recognized represents the district in which the Pfizer Global Research and
Development facility is located and has explored previous partnerships between Pfizer
and the HIV/AIDS Alliance located there.

Modifications to the Michigan Medicaid Changes presentation were also necessary to
prepare for presentation to the sales force. The docun1ents necessary to the understanding
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of this complex issues are to be explained if full detail, so the field force representatives
can assist physicians in the prior authorization process.

Developments
The Michigan Department of Community Health released a letter on February 11, 2002,
which detailed the Department's plans to postpone the implementation of the prior
authorization system.

While the communication included a schedule of proposed

implementation dates, the letter stated the system would not be enacted until "at least
February 25, 2002." [See attached.]

The Seniors Coalition, a vocal national organization of senior citizens, is planning to file
and amicus brief siding with the Phannaceutical Research and Manufacturers of America
in the lawsuit against the Michigan Department of Community Health.

Summary
While AARP's decision to side with the state of Michigan on the prior authorization issue
was certainly surprising and not of assistance to our efforts, the anticipated response by
the Seniors Coalition will be an asset to the campaign against prior authorization. In fact
some of the local AARP chapters have been contacting the state office with inquiries as
to why this particular position was taken. In addition, they are not pleased that the local
chapter constituencies were neither consulted nor infonned of this decision.

The phase-in announced by the Department is indicative of the pharmacy benefit
manager's inability to accommodate the prior authorization demand of the physicians and
their staffs and the Department's haphazard approach to implementing the program. By
phasing in classes of drugs, the Department hopes to be able to employ the program more
successfully than was done in the disastrous "testing period." Meanwhile, the various
aspects of the campaign against prior authorization are moving forward.
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STATE OF U'C;HIGAN

DEPARTMENT OF COMMUNITY HEALTH
LliWI6 CASS 8lJH.O'Mca
LANSING. I.I'C ...I(I.\,. . .,:1
JAMU /c. >U.vIiMAN. JR .• Oil..,,'"

Fcbru.ary 11.2002

Dear ProviderlPrescribcr:
On February 1. 2002. the Michigan DepartmCllt of Community Health beaan the implcrru::ot.ltion
of the expanded prior authorization pl'OgrBm for phannaccutical.s without denial of dzvp that
will require prior AuthorizatiOn.. The week of February J - 8 was designated as a testing period
and a time for prescribers to fax in or wi in prior auilioriution n:quests. This preimple.mentltion prior authorization period will be eXlcmdcd to Fcbn.wy 24. 2002. Thus. prior
authorization will not be required to fin prescriptions unlil at least February 25. 2002. On
Fcbcuary 25. 2002, the depautmcnt will begin phasiog in specific; drYg classes Rquiring prior
authoriution to dispense. The phase in will continue through March 18, 2002. The cbsses of
drugs ilI1d dates of implementation ofthc prior authori1.ation r~quircment are enclos~d.
Prior authorization may be requested for any of the drugs that will require prior authorization at
any time during this philse in by calting the First Healrb Services Corporation's [FHSq Clinical
Call Ccn~ at 1-877-864-9014 or by filXing yow requ~t to FHSC at 1-888-603-7696 or 1-8002S()..69S0. A fux. form is enclosed and may be duplicated for your usc. The fonn identifies the:
information \hat wiU be required to grant prior authorilation.
FHSC will prioritize prior authorization requests according to the phase in date for the
thernpcutic class of drug requested. Requests for drugs in the: February 25. 2002 phase in will be
addressed prior to requests for drugs from later phase in datl.:s.

Also cncloscd is a list of drugs th3t do not

~quirc prior authorization in most cases. W. urge
providers to prescribe from this list and only call for prior authorization when clinically
neccssmy .

Please note, drugs that required prior authorization before Fcbruary 1. 2002 will continue to
require prior allthorization, and all related edits will remClin in force. The dcparuncnt docs not
caVa'

refills until 7S percent of1hc prcvio\lj prescription has bten used.

For general questions regarding this prol:ram. provideu should contact the FHSe Tcc:hnical Call
Center at 1-877-624-5204.

[. 02-09

L 02·09 • AlI.1chmC:Dt

MichiglD Department of Community Health
Timeline For The rapeutic Class Phase ]n of the Implementation of tbe EJpanded Prior Authorization
February-1\larch 2002

February 25, 2002

AnrianxicTy
_ Antihistamines
G1ucocorticoids
Macrolides
' :""

March 4, 2002

eN S Stimulants

Oni HypogJycemics
1st Gen. Cephalosporms
2nd Gen. Cephalosporins
Angiotensin Receptors
Beta Blockc~
NSAlD3
Atypical Antipsychotic!;
Typical Aftlipsychotics

~1arch

11,2002

J\'farch 18,2002

Alzhcimers
ACE Inhibitors
Anti-fwlgals
Coronar}' Vasodilators

Iruulins
Anti-Hyperlipidemic Agents
Narcotics
Platelet Inhlbitol")
Quinolones
RespiratOlY Beta Adrenergic Inhalers
Sedative Hypnotics Non-Balbituates
- Steroids, Nasal
Steroids, Topica1
Topical Nitroglycerin

!!

PPIs

Anti-Depressants
Calcium Channel Blockcrs
Osteoporosis Agents
BipoJar Agents
Antivirals
H2 Antagon~ts

TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: February 25, 2002
RE: College Scholars Senior Project Report
Report
Additional partnerships with voluntary health associations have been fostered over the
past week. My initial contact with the Juvenile Diabetes Research Foundation
International (JDRFI) led me to believe that this organization would not be of much
assistance to the campaign against prior authorization; however, when I met with them,
they were extremely interested in the issue and its ramifications. The advocacy of this
organization tends to be on the national level, as their chief goal is to increase research
funds to find the cure of juvenile (Type I) diabetes. Their representative works closely
with other non profit groups because of personal health experience and referred me to a
small, but active mental health advocacy group, which she thought would be interested in
this issue and might possibly weigh in. JDRFI asked to be kept up to date on the issue
and was open to the possibility of making a position statement and involvement in a letter
writing campaign.

Through a joint meeting with the National Family Caregivers Association, the Well
Spouse Foundation, House Call Physicians and the Maria Madeline Project, I was made
aware of the priorities of these groups as they relate to home bound individuals. The
Well Spouse Foundation primarily focuses on providing emotional support to the spouses
of the disabled, while National Family Caregivers is similar in these interests and is
supported by Pfizer on the national level. House Call Physicians works hand in hand
with the Academy of Home Care Physicians, and provides service to Medicare recipients.
The Maria Madeline Project is an organization that has developed intergenerational
software for use at senior centers, nursing homes and retirement facilities. These groups,
with the exception of the Maria Madeline Project, are active members of the Chronic

Illness Coalition, and are very interested in the possibility of phannaceutical companies
taking a nl0re proactive role with this group. All the groups expressed concern over the
prior authorization issue and were open to relaying information on the failure of the
system upon its implementation. In fact, one of the Health Care Partners nurses at the
meeting indicated they had already experienced adverse patient care effects with their
clients during what was considered the "testing period". The groups were pleased to hear
about the Share Card and are planning to promote it to their populations.

Each group also had suggestions for possible partnerships with Pfizer.

The Maria

Madeline Project is interested in Pfizer moderating a chat room on their interactive
website for seniors (www.mariamadeline.com).

I indicated that I would make the

appropriate corporate contacts aware of this idea, and that upon the submission of a
proposal including budgetary figures, the grant review committee would consider this
possibility.

The site is currently providing medical advice through the Health Care

Partners group, as well as spiritual reflection and cooking expertise for seniors.
Partnerships with Ford Motor Company and the UAW have made the software program
available in two of their retirement centers in Michigan and Texas with plans to expand
to thirty-one national centers.

House Call Physicians expressed interest in a Pfizer representative presenting on the
Share Card at the annual conference of the American Academy of Home Care Physicians
and the American Geriatrics Committee in May, while the President of National Family
Caregivers and the Chronic Illness Coalition would like Pfizer to present on the Share
Card and prior authorization issue at one of the bimonthly meetings and their semiannual
forum. In addition, they are interested in sponsoring a special event at which celebrity
physician and founder of Gesundheit Institute, Patch Adams would be the keynote
speaker.

The National Organization for Rare Disorders has been, up to this point, a solely national
organization. The Michigan state branch, which is presently in the development stage,
will serve individuals diagnosed with any of 6,000 rare disorders in tandem with the
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national organization on state level issues. The Michigan state branch is to serve as a
model for all other state branches and is now beginning to identify and consider state
issues. Their representative was opposed to the prior authorization policy from both a
personal and organizational standpoint.

She is planning to submit the issue to the

national office to receive authorization to weigh in, but regardless will personally write to
indicate her opposition to the policy.

The organization is in favor of research and

development due to the necessity of innovative treatments to be used in search of cures
for rare diseases, and thus hopes to cultivate a relationship with Pfizer for the benefit of
the organization's population.

Summary

The organizations I have met with over the past week have proven to be valuable assets
with beneficial insight and networking capabilities. Each is unique in its focus, but the
common goal of quality patient care results in partnership possibilities of benefit to their
organizations and Pfizer. The groups have all been very interested in hearing the status
of the prior authorization process, since it has the capacity to impact their constituents
with such gravity. The Share Card is of interest to them as well due to their interaction
with disabled individuals who are Medicare recipients as a result of their disability. It is
exciting to see the tie-ins and be able to develop a network of individuals with such
amazing potential to effect change within their given niches.

Developments

The implementation of the prior authorization process is scheduled to go into effect
today, February 25, 2002.

It will be interesting to see if the phase-in approach is

successful in alleviating the problems experienced during the initial implementation
procedure.

Since the initial implementation, contact with the voluntary health

associations and senior centers has been solidified through the initial coalition meeting
and follow up communication, and through this network we hope to be able to
communicate the experiences of individuals who are adversely impacted to state
government officials as quickly and efficiently as possible.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: March 4, 2002
RE:

College Scholars Senior Project Report
Report

The coalition in opposition to the prior authorization policy implemented by the state on
February 25, 2002 is now at the point of incorporation. Last week the government policy
firm under contract with Pfizer in Michigan drafted the articles of incorporation for a
group titled 'Senior Citizens for Prescription Drug Fairness'. At the direction of the
Manager, State Govemn1ent Relations, I extended offers to participate on the leadership
con1mittee of this organization to four individuals, two senior center representatives and
two voluntary health association representatives. One representative, who works with the
Visiting Physicians Association, the largest home care physician network in the nation,
accepted promptly and is excited about the position. In addition, one of the senior center
representatives who had asked that a presentation on the Share Card be made at the
Senior Leaders conference and also attended the initial coalition meeting has agreed to
serve. The other two individuals have yet to respond and are waiting for a formal written
offer detailing the leadership position.

The Share Card shipment that had been temporarily delayed due to the overwhelmingly
positive response the program arrived this week.

Thus, over 3000 brochures were

repackaged and mailed out in the requested quantities to those represented at the coalition
meeting and others who were unable to attend that day.

A few of the sixty plus

organizations that received brochures have already utilized this initial supply and are
sUbmitting requests for additional brochures.

The contracts for the consultant firms engaged in the campaIgn against pnor
authorization were found to need revision, and after this project was completed, they
were forwarded to the campaign coordinator for his final review.

The President of the Maria Madeline Project, the intergenerational technology program,
submitted a proposal detailing the possible partnership with Pfizer. I sent this proposal to
the New York office of Civic Affairs to be reviewed by the grant review committee. This
committee regularly considers all philanthropic partnerships presented to Pfizer and will
determine whether or not moderating the ExperienceSeniorPower chat room opportunity
will be pursued.

A regional meeting with the Western counterparts called for presentation materials on the
status of supplemental rebates in different states. I assisted with the graphics in the
presentation, which provided an overview of the current situation in California,
Michigan, Florida and Illinois.

The representative from the Juvenile Diabetes Research Foundation International had
inquired as to which insulin treatments required prior authorization.

I located this

information on the changes to the Michigan Medicaid formulary and sent the requested
information.

Developments

On Friday, March 1, 2002, one of the district managers informed our office that a
member of the Pharmaceutical and Therapeutics Committee had relayed that Zoloft and
the other drugs in the SSRI class had been carved out from the prior authorization policy.
The behavioral drugs are now to be grand fathered in, and only those individuals who are
receiving prescriptions for the first time will be required to go through the prior
authorization process. This was a notable development, but has not yet been confirmed
with the state Medicaid office. I placed calls on Friday to the appropriate state employees
to verify the assertion, but have not yet been able to confirm this change to the policy.
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Summary

The campaIgn against pnor authorization is continuing to develop, however,
simultaneously negotiations with state officials regarding alternative solutions are
underway.

While no consensus on this front has yet been reached, both sides are

attempting to find a solution. It would be advantageous to reach a compromise without
the full blown campaign due to the possibility that such a canlpaign has the inherent risk
of alienating the state and prompting those implementing the policy to become further
entrenched in their position. Due to the uncertainty of the negotiations, the consultants
and the coalition are still fully engaged and prepared for a campaign.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
DATE: March 11,2002
RE:

College Scholars Senior Project Report
Report

The week began with a presentation over lunch to employees, including physicians,
pharmacists and other staff of one of the Community Mental Health facilities in the
Lansing area. These individuals are most directly involved with Medicaid patients in
need of mental health care and in this capacity have had experience with the prior
authorization process firsthand for an extended period. Their reports confirmed that the
process has serious ramifications for mental health patients, and they were interested in
drafting a document so that they could track the prior authorization process in a uniform
manner. They raised the issue of the patient's right to appeal and exchanged suggestions
on how to submit a prior authorization request so that it would have a better chance of
being approved.

In meeting with the Michigan Psychiatric Society, I learned that the state had postponed
the implementation of the process the first time due to the fact that they had not given the
Medicaid recipients the federally mandated ten days notice. In addition, the vague nature
of the letter that was subsequently sent to Medicaid recipients left many in a state of
panic and confusion. It is reported that the pharmacy benefit manager received over 900
calls the first weekend from individuals concerned that they would not be able to access
their current medications.

Some individuals even called cabs and showed up at the

Community Mental Health facilities in hysterics because they were so concerned. The
seventy-two hour emergency prescription provided for in the pharmacy benefit manager's
contract is not being honored by some pharmacies due to the inability to be reirrlbursed
for the expense, and now at least one of the health management organizations has
implemented a prior authorization system prior to the state-mandated schedule. It is

rumored that the HMO's, which were supposed to have the prior authorization system
implemented on April 1, will now not be participating in this program until next year due
to the disastrous effects experienced on the "fee-for-service" side. As anticipated, some
primary care providers are now refusing to see Medicaid patients due to the increased
burden on the physician and their staff.

They have been sending these patients to the

Community Mental Health facilities, where the caseload is already high. The Michigan
Psychiatric Society representative provided me with infonnation on a public hearing
being held by the Michigan House's Health Policy Subcommittee on Increasing Access
to Quality Health Care at which many of the health advocacy groups are planning to
testify. She also provided a draft of a prior authorization tracking fonn.

A presentation on the Pfizer Share Card was made to the Senior Leaders Conference on
March 7, 2002, and the group was enthusiastic about this new initiative. Many reported
that seniors were already inquiring as to how to enroll in the program and were glad to
have been able to ask questions and receive program infonnation. The senior leaders
provided valuable insight on how to improve the program for seniors, such as allowing
the senior center representative to fill out the application for those seniors who have
difficulties with such tasks.

A meeting with the contract lobbyist finn on the incorporation of the coalition was held
later in the week, and the details of the incorporation were discussed.

I received

acceptances of the invitation to serve on the board of directors from all of the seven
individuals to whom I extended an invitation.

The leadership committee of this

organization will consist of representatives from the Visiting Physicians Association,
Michigan Association of Senior Centers, NAACP, Epilepsy Foundation, Health Care
Partners, National Kidney Foundation of Michigan and the Chronic Illness Coalition.
This group is excited about their leadership role in the Senior Citizens for Prescription
Drug Fairness and is scheduled to participate in a conference call in which officers will
be appointed and the goals of the organization fornlalized on Monday, March 11,2002.
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In addition, I participated in a conference call of the campaIgn participants.

The

campaign calendar has been determined and the first informational luncheon for senior
citizens in the Detroit area will take place on March 19, 2002. Some 300 seniors are
being invited to attend and media will be present to cover the event.

The coalition

leadership will have the opportunity to participate in this event.

The Seniors Coalition is planning to file their amICUS brief on the side of the
pharmaceutical companies in the lawsuit against the state within the week. The group is
also presenting policy socials at senior centers throughout the state on the prior
authorization issue and will conclude with a press conference in one of the state senator's
offices tomorrow. This group is opposed to prior authorization and has been extremely
active in informing the senior population about the possible negative effects of this
policy.

Developments

Confirmation of the grandfathering of the antidepressant class was received, meaning that
individuals who are currently stabilized on such drugs will not be subject to the prior
authorization process. The state employee overseeing this aspect of the implementation
has had experience with mental health disorders within his immediate family, and he was
reported to have said that he would not want his family member to be forced to switch
medications due to the length of time required to find the proper combination of
medications.

Summary

The alternative solution continues to be explored, however, due to the uncertainty of the
outcome, the campaign is being implemented.

The past week had many promising

developments and in n1eeting with the various groups, crucial information to the
campaign against prior authorization was gathered.

The health advocates and senior

center representatives on the board of directors of the coalition are excited about the
opportunity to serve and will be more formally introduced to each other within the week.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
RE:

College Scholars Senior Project Report

DATE: March 19, 2002
Report
The individuals who have agreed to serve on the Board of Directors participated in their
first meeting by conference call along with the Director of Government Relations, the
contract lobbyist and myself. At this time officers were appointed, and the goals and
objectives of the organization, scheduling a Detroit Seniors Day and extending invitations
to other organizations were discussed. The group also talked about legal aspects of nonprofit corporate involvement and scheduled the first meeting of the board. They were
interested in targeting legislators who would be influential in the budget process and
understood the timeliness of the issue at hand. I began preparing a presentation that
would subsequently be presented to the group on the prescription policy in Michigan.
[See attached]

I also met with a mental health advocacy group on the West Side of the state later in the
week. This group consisted of a city commissioner, several health professionals who
regularly deal with the Medicaid population, an environmental engineer and mental
health advocate, a minister and a Medicaid patient.

This group has experienced the

adverse impact of the prior authorization system and is interested in being a part of a
coalition movement. Although the group has not yet weighed in on the issue, they are
plarming to organize a public forum to which legislators and other public officials will be
invited. They extended the invitation for me to attend their meetings on a regular basis
and also asked to be updated on hearings and other opportunities to testify on the process.

The Subcommittee on Increasing Access to Quality Health Care held a public hearing
entitled "Access to Pharmaceuticals." In this hearing, one of the members of our Board

testified on the prior authorization system on behalf of another coalition of which she is
part. The Michigan Psychiatric Association, Mental Health Association and Michigan
Association for Children with Emotional Disorders also provided input on the recent
changes. The legislators were interested in obtaining definitive data that would indicate
the current system is not working.

The Seniors Coalition, a national grassroots advocacy network, completed their statewide
tour of Michigan with a press conference in the Capitol. The group's spokesperson is
seventy-nine year old Grandma (Flora) Green. She travels with her staff from state to
state informing seniors of policies that will impact them and their access to health care.
In Michigan, they have held policy socials on the prior authorization system and
partnered with a state senator and practicing physician for the press conference. I was
able to attend and had the pleasure of meeting Grandma Green. This group is also filing
an amicus brief in response to the AARP amicus brief filed on the side of the state. [See
attached article]

A public policy coordinator from the Civic Affairs division came to meet with me and
discuss the progress of the coalition.

She provided several good contacts and some

valuable insight on the process of coalition building. The proposal submitted to Civic
Affairs on behalf of the Maria Madeline proj ect was discussed. This proposal was also
forwarded to a district manager in the Ann Arbor area for his review. He indicated that
due to the FDA regulations prohibiting the giving of pharmaceutical advice to anyone
other than health care professionals, this proj ect could not be pursued. I relayed his
comments to the Civic Affairs contact so that she would have this feedback prior to the
submission of the proposal to the grant review committee.

I also participated in conference calls between the Director of Government Relations and
the various consultants throughout the course of the week to update them on the progress
of the coalition, and spoke with members of the field force on the prior authorization
issue and our efforts.
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Developments

The alternative that was drafted by the Senate Appropriations Subcommittee on
Community Health staff and with input from our office has passed out of the Senate
Appropriations Committee and is now to be reviewed by the full Senate.

This

compromise would allow the state to receive Medicaid best price for all taxpayer funded
programs and has the possibility of remedying the current pharmaceutical budget
shortfall. This is seen as a positive solution for everyone involved.

In addition, my immediate supervisor has decided to take short-term disability leave due
to a health condition. This has resulted in an increase in my workload due to the gravity
of the prior authorization issue.

Consequently, I have been asked to participate in

conference calls more frequently so that his direct supervisor is aware of all current
developments and have also been trying to keep the consultants up to speed on the
coalition progress.

Summary

The formalizing of the coalition has been a very detailed process with numerous legal,
financial and personal issues. The group is very vocal and educated on health care and
senior related issues and I am optimistic that they will be of great value to the cause of
increasing access to pharmaceuticals in the short and long term. It has been challenging
to make sure that the concerns and requests of the all of the individuals involved in the
process are taken care of, since there are occasionally opposing views on how
information should be conveyed and issues should be handled.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
RE:

College Scholars Senior Project

DATE: March 25, 2002
Report
Before the first fonnal nleeting of the Board of Directors for Prescription Drug Fairness,
an infonnational briefing on prior authorization was sent out via email. The agenda for
the first meeting was drafted and submitted to both the Director of Government Relations
and the ChairpersoniPresident of the coalition.

The ChairpersoniPresident of the

coalition has had experience in health care administration and requested further
infonnation on how similar undertakings in other states have been facilitated.

In

response to this inquiry, a representative from the Pfizer Civic Affairs division in New
York was asked to be present at the meeting to field any questions along these lines. The
presentation on the Michigan prescription policy was approved by the Director of
Government Relations with a couple of minor changes, and consequently an
infonnational packet for the Board of Directors members was assembled, including a
contact list, examples of the required prior authorization fonns and a hard copy of the
presentation.

I met with the branch manager of the statewide bank chosen by the Board of Directors to
obtain the paperwork necessary for opening a corporate checking account. He indicated
that it would be helpful if the Board of Directors menlbers who would serve as signors on
the account were present at the time the account was opened due to the need for personal
infonnation.

I relayed the infonnation provided by the bank to the Director of

Government Relations and the Campaign Coordinator by conference call, and they were
in favor of the ChairpersoniPresident and the Treasurer having access to the funds
available.

The first meeting of the Board of Directors began in the morning at the offices of the
media relations firm in Detroit. Six of the seven directors were present, and the meeting
opened with the presentation on the Michigan prescription policy.

The consultant

coordinating the campaign against prior authorization was to follow this presentation
with an overview of the campaign plan, but due to transportation diffculties had to make
the presentation by conference call. Following his presentation and questions from the
Board, the government relations firm fielded questions on lobbying requirements. The
media relations firm then explained the senior luncheon aspect of the campaign. The
Board concluded the meeting with two motions:

the first being the approval of the

conceptual design of the campaign as presented and the second the scheduling of the first
senior luncheon in Detroit on April 4, 2002.

Due to the inability of the Director of Government Relations to be present at this first
n1eeting, a conference call was held involving all parties who presented to the coalition at
the first meeting. The general consensus was that the group, in addition to being well
educated on the issue, was politically astute, and it was agreed that following one more
meeting they would be prepared to kick off the media campaign at Detroit Seniors Day.
The second meeting was scheduled for March 26, 2002 at the offices of the government
relations firm in Detroit. This meeting would involve the Board of Directors as well as
the Campaign Coordinator, two men1bers of the New York Civic Affairs team, the State
Government Relations managers from Indiana and Ohio, and the consultants responsible
for lobbying, direct mail and media relations. The goals of this meeting are to introduce
all the key players in the campaign, submit the campaign plan to the board for review and
input, as well as formally establish the coalition.

Another conference call with the State Government Relations managers from Indiana and
Ohio was held late in the week to bring them up to speed on the Michigan issue in the
absence of the Michigan State Government Relations manager. The oversight of the
Michigan field force was delegated to the Indiana manager, due to his preVIOUS
employment in that capacity prior to holding the government relations position.
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Information regarding the prior authorization status of Pfizer products and all previous
communications from our office to the sales force were forwarded for this purpose.
Developments

Unfortunately, one of the directors of the coalition resigned the position late in the week
due to her organization's conflict of interest on the prior authorization issue.

The

voluntary health association of which she is employed has a large line item in the
Michigan Department of Community Health budget, which constitutes a substantial
portion of the organization's operating budget.

This organization has historically

partnered with Pfizer on the state level and was forced to make a difficult decision. She
indicated that she was personally opposed to the prior authorization policy, but could not
participate as a representative of her organization.

Summary

As the Board of Directors reviews and tailors the campaign against prior authorization,
they are being directly connected with the consultants involved with the campaign. As
this progression takes place, my role shifts from founding and organizing interested
parties to serving as more of a resource for the group as they define their organizational
parameters. While I provide information and serve as an intermediary for between the
Board and the consultants, this role is continually diminishing as the consultants assume
the direct responsibility of their various aspects of the campaign and advise the Board of
Directors on these matters.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
RE:

College Scholars Senior Project Report

DATE: Aprill, 2002
Report
In preparation for Tuesday's coalition meeting, I spent most of Monday gathering
documents which answered questions raised by the Board of Directors at the previous
coalition Ineeting. This included a sumn1ary docun1ent of the RFP process by which First
Health was selected, as well as a list of the Pharmaceutical and Therapeutics Committee
members who were appointed by the Governor to determine the "best in class" drugs. In
addition, articles of incorporation were made available for their convenience.

The second board meeting was extremely productive, despite the inability of three of the
board members to attend due to illness, prior engagements and religIous holidays. That
morning I met with the senior account manager of the Civic Affairs division to discuss the
coalition and the steps that had led up to the current situation. His previous involvement
with a like coalition in Washington State provided helpful input, and he was able to attend
the board meeting to give input on how grassroots advocacy had been successful in other
states.

Prior to the Board meeting, I met with the Secretary who was unable to attend, so that she
could sign the necessary bank documents.

The meeting began with a presentation on the recent grassroots

defea~

of a Medicaid prior

authorization policy in Washington State-a program more restrictive than the current
Michigan plan. The board members had questions as to how the patient advocacy coalition
had begun and gained credibility and subsequently discussed opening the membership of
the coalition to gather a broader base of organizations, in addition to looking into other
sources of funding.

A legislative update on the alternative, which passed out of the Senate prior to the Spring
Break was then given. The alternative would extend the Medicaid "best price" rebate to all
taxpayer-funded programs.

In return for the participation of the pharmaceutical

companies, each company that chose to extend rebates to the state 1 un programs would
receive unrestricted status on the formulary. Several pharmaceutical companies have
indicated that they would be interested in participating in this alternative. The board was
very supportive of the alternative and felt that it relieved many of the current program's
issues while providing the state with the revenue necessary to alleviate the budget shortfall.
The members had input on the prior authorization program's current shortfalls--such as
inefficient response time; in fact, the Chairperson/President of the coalition had spend over
thirty minutes on hold when attempting to receive approval for an elderly woman who had
been stabilized on Glucotrol for diabetes. She felt very strongly that the coalition should
support the alternative legislation, as did the representatives from the two senior centers
present.

The campaign plan as developed with a Senate focus was then discussed, and it was
decided that such a strategy was no longer relevant. A House strategy was thus drafted
with the coalition member's input, and the senior lunches as scheduled were cancelled with
the exception of one. The coalition was conflicted on the issue of media involvement, as
some felt that they were not yet ready to undertake such a campaign, while others asserted
that media could play a key role in mobilization efforts. Direct mail pieces were also
scrapped due to the relatively short time frame within which the alternative would have to
be advocated.

The necessary parties signed the bank documents, and I had a bank employee and legal
counsel review them prior to forwarding them to the treasurer who would open the
account.

Later in the week, I then drafted the unrestricted grant request that would

ultimately be submitted to the Director of State Government Relations by the officers of
the coalition and sent it to the President/Chairperson for her review.
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In addition several conference calls were held between members of the coalition and the
parties involved in the forming of the coalition. It was decided that regular communication
between all involved would be the best way to remain up to date on the coalition and other
aspects of the campaign. The campaign coordinator then formulated a list of tasks to be
completed by each of the consultants and Pfizer employees in order to ensure that the
schedule set forth was maintained.

Summary
The coalition members are extremely vocal and can be counted on to provide valuable
input. They are also politically savvy and fully comprehend and consider the scope of the
implications of their actions. Many of them have been active in advocacy prior to this
campaign and have significant health care expertise. It is a constant challenge to make
sure that their questions are answered, in addition to the internal responsibilities.

Developments
The coalition members have decided to hold legislative breakfasts within their districts that
will target the members on key committees with respect to the legislative alternative.
These breakfasts will include a cross section of health care professionals who can attest to
the shortcomings of the current prior authorization and the adverse impact on patients, as
well as the increased staff time required to ensure that quality health care is being
practiced. These breakfasts will provide a forum for the professionals to indicate their
displeasure with the prior authorization system and their support of the program that would
be put in place by the legislative alternative.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
RE: College Scholars Senior Project Report
DATE: AprilS, 2002
Public Policy Report: Washington State
Due to the impact of the policies enacted or eliminated by other states on the political climate
and thus, decisions regarding critical public policy issues in the state of Michigan and others,
a study of the state of Washington provides valuable insight. Subsequently, the defeat of the
prior authorization system in Washington can be utilized as a model for a successful
campaign against prior authorization and as a tool for learning how to advocate appropriately
against an issue. While an identical outcome is not guaranteed by any means, the process by
which the ultimate goal was achieved in Washington can be patterned in Michigan following
careful consideration of each aspect of the campaign, while maintaining a sense of the broader
Issue.

The Washington legislation included mandatory therapeutic substitution, a preferred drug list
and prior authorization which is similar to the current Michigan prescription policy mandating
prior authorization for all drugs not included on the preferred drug list or explicitly
grandfathered. The initial response in Washington to these impediments to access was an
attempt to amend the bills so that they would be more palatable; however, when this tactic
proved unsuccessful, the goal became to eliminate the legislation.

The negativity of the

public policy was emphasized, as well as the potential to adversely impact other states that
might follow Washington's lead.

The following is a more detailed analysis of the actions

taken in Washington.

Efforts were coordinated on a number of fronts including the print media, the biotech
industry, Voluntary Health Associations, the NASDAQ, Pharmaceutical Research and
Manufacturers of America and the Pfizer sales force.

Through the collaboration of these

groups, a groundswell of opposition to the policy was evidenced, leading to the ultimate
demise of the policy. Those opposing the legislation would support measures such as targeted
disease management in hopes of reducing long-term costs and enhancing the quality of life, as
opposed to restrictive measures focusing more on the short ternl.

The policy was not opposed by all; in fact, some key groups supported the changes, including
the local chapters of the American Heart Association, American Lung Association and the
American Cancer Society, along with the state medical association, pharmacists and labor.
These supporters based their position on the need to do something to address the rising cost of
pharmaceuticals, a consideration undisputed by many of the opponents.

A voluntary health association coordinator was employed to hring together those
organizations opposing the policy, among them: the American Diabetes Association, Epilepsy
Foundation, National Alliance for the Mentally Ill, Paralyzed Veterans of America, National
Association of Black Veterans and others. In addition, position papers were written by the
National Venture Capital Association and the biotech industry asserting the belief that the
policy would have a negative impact on the economy. Seattle is one of the two largest
national biotech markets; thus, an interest in the effect on this aspect of the economy was no
doubt of great inlportance to legislators and other state officials.

The National Alliance for the Mentally III undelWrote the cost of transporting members of the
minority community to Olympia in order to testify to the legislature. The press characterized
this action as "playing the race card," which was promptly answered by an opinion editorial
asserting that legislators were attempting to minimize the legitimacy of the issue.
Consequently, the minority press opposed the legislation, and members of the minority
community effectively lobbied their state legislative officials.

The sales force was informed through several action alerts providing them with form letters to
distribute to physicians and their staff, so that these individuals could express their
dissatisfaction with the changes in the health care delivery requirenlents. Talking points were
developed regarding the economic, political and social implications of the policy and were
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distributed to various audiences, including the GOP caucus. These documents detailed the
difficulty presented to individuals seeking an exception to the policy, as well as, the minimal
dollar figure anticipated in savings by the state of Washington.

An alternative was also proposed, which invalidated the assertion that the phannaceutical
industry will not advocate options resulting in savings to the state. In fact, the contracting
finn identified over $50 million dollars that could be saved by the state of Washington
through the enacting of programs that would not inhibit phannaceutical access.

Clearly, similarities exist between the Washington and Michigan policies, such as:
•

Restrictions to phannaceutical access

•

Minimal savings being realized by the state through changes enacted

•

Adverse impact on Medicaid population, especially the minority community

•

Mixed review among voluntary health associations, with strong groups represented on
both sides of the issue

•

Alternative legislation which offers a solution to the current issue

It is important to note as well the conflicted media messages that fueled the issue and

increased the public's awareness. While some print media in Michigan has covered the issue,
polling indicated that much of the public is currently unaware of the two-tiered health care
system created by this type of policy.

The response to the Michigan pnor authorization has mirrored that of the Washington
reaction, in that an alternative has been proposed and is now being considered by the
legislature through the budget process. It is advantageous to assure legislators of the necessity
of supporting this alternative. At the current time, members of the House Appropriations
Committee are being invited to legislative breakfasts initiated and coordinated by directors of
the Senior Citizens for Prescription Drug Fairness to ensure that the issue is appropriately
understood and addressed by the legislators in the budgetary process to come.
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TO:

Dr. Harold Black
Dr. Bob Cunningham
Dr. David Tandy

FROM: Hannah Kiser
RE:

College Scholars Senior Project Report

DATE: April 15, 2002
Report
The Michigan Department of Community Health presented their budget for the fiscal
year 2002-2003 on Wednesday, April 10 to the House Appropriations Subcommittee on
Community Health. The Michigan Pharmaceutical Best Practices Initiative consumed
the majority of the discussion, and the Department released a twelve-page document that
provided their analysis of the prior authorization program's results to date. In addition,
the Department asserted in their testimony that there had been no appeals or con1plaints
of negative consequences resulting from patients being switched from a restricted drug to
an unrestricted drug.

They anticipate that the volume of calls to First Health will

decrease as compliance with the preferred drug list is achieved and indicated that calls
with technicians now average between three and a half to five minutes per call.

When asked about the cost savings being realized by the state, the Director commented
that the program had only been in place a few weeks, and consequently, he would prefer
to disclose this information at a later date. Questions were also raised as to how the drugs
were selected for preferred status, whether or not cost considerations were formally
utilized in this process, and the reasoning behind the lack of public input. At this point in
time, control groups have not been employed to ascertain the effect of the program on
Medicaid patients.

Interestingly, a recent study by the Center for Studying Health

System Change, which is funded by the Robert Wood Johnson Foundation, indicates that
barriers to access such as prior authorization, prescription limits and step therapy have a
higher impact on the Medicaid population due to low income and chronic illness
considerations. [See Plint Media.]

Public input hearings will be held on April 17, 2002 and April 24, 2002.

This will

provide health care professionals and consumers the opportunity to present their
experiences with the prior authorization system.

I met with the Mental Health Advocates group in Grand Rapids later in the week, at
which time I was able to inform them of the current alternative legislation.

Several

individuals were extremely suppoliive and plan to attend the public input hearings to
rebut the testimony given by the Department.

I also extended invitations to the

legislative breakfasts in their districts, and they are interested in attending these as well.
Another topic of discussion at the meeting was the Medicaid waiver which would draw
down federal funding--allowing many of the currently uninsured in Michigan to be
eligible for Medicaid. The waiver has drawbacks, however, and several mental health
groups are in opposition.

A representative of the Michigan State Medical Society contacted our office with a
request for sponsorship of the annual Capitol Checkup. He indicated that this year's
theme would be pharmaceutical access, specifically prior authorization.

When asked

what the group's position on prior authorization was, he reported that many of the
physicians are frustrated with the current policy due to the increased burden on their
staffs.

He went on to say that the best solution would be the legislation involving

pharmaceutical companies paying Medicaid best price rebates to all state funded
programs as it would replace the prior authorization system with unrestricted access for
the participating companies.

In addition, I participated in several conference calls involving both the coalition and
other groups. Several mental health groups are in the process of setting up a toll free
number, so heahh care professionals, consumers and caregivers can relay their stories
about the prescription policy. The volume of the calls would then be used to convince
legislators that the policy has not functioned in the way the Department presented both
prior to and after its implementation. The coalition members have located leaders for the
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small breakfasts with legislators, and it seems that a variety of constituents will be
present to educate legislators on their experiences.

Developments
Up to this point, the Pharmaceutical Research and Manufacturers of America have been
neutral on the legislative alternative. There have been reports that some of the larger
companies which provide deep discounts are now in opposition to the legislation and that
PhRMA may, in fact, oppose the legislation openly. Despite this development, Pfizer's
position would remain unchanged, and the campaign against plior authorization would
continue without alteration. PhRMA is not advocating any other solutions or alternatives,
and would simply be in opposition to both the current policy and the alternative.

Summary
The campaign against prior authorization has evolved into advocacy for the alternative
legislation.

The representatives with whom breakfasts have been scheduled were the

most inquisitive of the Department at the hearing, and it has been reported that many
legislators feel as if the Department had misled them regarding prior authorization. The
legislative breakfasts, opportunities for public input and toll free number should provide
means for the public to communicate their displeasure with the enacted policy.

The

process of informing legislators is now in action, and the outcome of this process will
primarily determine the ultimate conclusion with regard to pharmaceutical access in the
state of Michigan.
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Abstract Background. Many state Medicaid programs
limit the number of reimbursable medications tt1at a patient can receive. We nypotheslzeu that such limitatione
may lead to exacerbations of illness or to admissions
to institutions where there are no caps on drug reim. bursements.
Methods. We analyzed 36 months of Medicaid claims
data from New Hampshire. which had a three-drug limit
per patient for 11 of those months, and from New Jer~ey,
which did not. The study patients in New Hampshire
(n = 411) and a matched comparison cohort in New Jersey (n II: 1375) were Medicaid recipients eo years of age
or older who in a base-line year had been taking three
or more medications per month, including at least one
maintenance drug for certain chromc diseases. Su.vival
(defined as remaining in the community) and time-series
;:'n::tlyses were conducted to determine the effect of the
reimbursement cap on admissions to hospitals QmJ IlursIng homes.
Results. The base-line demographic characteristics
of the cohorts w~re nearly identical. In New H<lmpshire,
ONCERl~

AD~lISSION

has mounted tJlat cost·containrnc:uL

policies implemented during the 19aOs may be
compromising th~ quality of care and the heahh of
vulnerable populations, such as poor and chronically
ill elderly pc:ople, although few studies have examined
this qucsllOll.1.2 Cha.rgee to the pAden,. ()f monthly 1imits on medications a.nd other "optional" services are
characteristic of most Medicaid programs. 3 Although
such restrictions on specific servit:c::s ~ould incrcQ~e
admissions to hospitals and nursing homes among
chronically ill elderly people, this has not been demonstrated in a controlled study. Decades of chnical research and experience document the effectiveness of
nlc:lny medication, in tre<' ring hoth acute life-threatening illnesses and chronic debilitating conditions. ~G
Lack of compliance with drug therapy has been associated wJth increased autul~sion3 to hocpit:).l& and
nursing homes. 7-10 Logica.lly, then, policies that red uce
access to effective medications may increase the race
of adverse clinical outcomes and the accompanyin~·
costs.
.
In an earlier studyll we examined the dl'ecrs
a
three-drug pa.yment 1imit, or cap, on the use of med-

of
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the 35 percent decline in the use of stUdy drugs after the
cap was applied was associated with an increase in rates
of adm.i~~inn to nursing homes; no changes were observed in the comparison cohort (AR = 1.8; 95 percent
confidence interval, 1.2 to 2.6). There was no signifioo.ntly increased ri~k of hospitalization. Among the patients in New Hampshire who regularly took three or more
study medications at base line, the relative risk of admiesion to a ntlrsing home during the period of the cap
was 2.2 (95 percent confidence inteNaI. 1.2 to 4.1). and
1ne risk of hospitalization was 1.2 (95 percent confidence
inter/ai, 0.8 to 1 .fi} . When 1he cap- was discontinued
after 11 months, the use of medications returned nearly
to base-line levels, and the excess risk of admission
to Q nureing home Ct;l:;l~P.rl . In general. the patients who
were admitted to nursing homes did not returnto the community.
.
ConoJueiom;. Limitif'lD rAimbursement for effective
drugs puts frail, Jow-income, elderly patients at increased
risk of institutionalization in nurSing homes and may inerC~E:e Medicaid costs (N Engl J Med 1991 ;325:1072-7.)
ication~ ~mong 10,734 Mpdica.id patients in New
Hampshire. Among 860 recipients of three or more
drugs, the cap was associated with significant reductions in the recci}.ll v[ several import~t medic:a..tiC'ln~
(e.g., 28 to 30 percent reductions for insulin, thiazide:;,
and furosemide) that were not otTset by incrr:ased OUtor-pocket purchases. When a copayment u[ :s 1 jJcr prescription replaced the cap one year later, the use of
most agenr~ 111lickly approached pre cap rates.
In that study, dara were not available to measure
possible changes in usc: of institutional seZ"v·ices. One
hypOUlt::).lzcd effect of the C3.p wu an in('T"::l~~ in nursing home admissions, due either to deteriorating
health or to a desire to shift to an environment exempt
from rhe cap. If the loss of eS::ic.mla.l ulcdication3 led to
an acute deterioration in health, one might also expect
inC"rp.ase(] hospiral admissions . In che current study,
we analyzed 3.6 months of additional nondrug dairoS
andenrellment data. from Medica.id to an~wer (he fol~
lowing ql.le~tion: Among lnw-incnme. elderly l\ledi·
caid patiems, is limiting access to medications associated with increased rates of admission to llursing

homes and ho:)pnals?
METHODS

Study Design .

This ~tudy u.scd survival (defined as remaining in the eommucity) and InCC'TruI-'LC:U liL\\,-~c;ric3 o.n.l.ly~~~ eo ev:...lll~[~ rn ..... ITpcts of [he
drug-payment r~triction. Outcome daa included 36 months UuLy
1980 caJunc 1983) of p!ltientS' nursing hom~ and hospital inpa.ti,nt
cJaimD in twn ~r~rl': Mcdic&id proer61ms. \Ve comp:ared Ule rstc: of;

a.dmission to nursing hOllle3 and hospit.lls before, d1Jrin~ . ana ;J,!ter~
rhc c~p in ~ defined cohort of chroniclJly ill dderly' pJticl'l:S in the,;
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study state (New Hsmpshire) with ·the rate in an idcnticalJy dc6~ed
eUllat'.u':.uu cohort in ~ JUiCe. 'Without A cop (Ncw Je~cy).
The three-drug payment limit implemented by New Hsmpshire
,Medicaid during month. 15 to 25 of the 36-month ,tudy period is
~mhM in dl"uil in our previous report. U With less than two
months' notice ta providers ~nd parients, the legjdsrivcly mandated
cost-containment me~ure restricted most Medicaid p~tients to
three prescriptioDs per month. After 11 m.onths the cap was eJimin3ced and replaec<l with I cop3yment of 11 per prescription. The
comp.uUol1 slate, New Jersey. was the only northeastern state
whose Medicaid program had no cost-wring requirements or payment limita.ti.ans fOr drugs durlng rhe 4tudy pcricxJ.
Availability and Quality of Data

Data on enrollment, the usc of study drugs, and hospital and
nursing home ildmisslons c~e from the c.'Omputeri%.ed McdicOlid
msnagement inCo(m~tion systems of the two,tatcs. EnroUmeDc files
were used to determine the age. so:, race, and category or enrollment of the patients, according to study month. Previow report!
indicate that data rlOm the Medicaid ma.nageJnent informstion 1)"&0tenu arc niply reliClble Qnd v~id Cor ftudyi", the precerib4ng of
drugs or admi$,ion to nursinG' homes.I%-I' Drug cJsims identified the:
product. number of units dispensed, patient, and date.
Fo~ evtry Medicaid rC:-3ident of skiUed-nuTsinl' and intermediate:arc ucilities, a monthly caim is submitted by the nursing home
prO\oider for basic ,ervlCCi. Because the study population 'Was already eligible for Mcdicld at the beginning of the study, any nUDinS' bomc !(sy wDuld automatkally be rclmbursed. Irom the tlrst
month of residence; we rhus svoided the problml of miuing d~ [~
during periods whc:n patients must ~pend their resources in order
\\1

,coach eligibility

Icvcl~.

Since all the members o( the scudy cohorts Were eligible for both
Medicare and Medjcaid. Medicare ws.s the primary p~yer for hospitAl ~rvit:,..\. The Ma:dicaid mana~ent information systems conuin. cUta on aU !uch services for which Medicaid paid a deductible
)Z' coiMunnc:c amount. For the first inpatient sdmission in ea.ch
spdl of iIInc:5s, Medicaid polyS 3 fixed deductible amounl We used
the Medicaid data to determine inpstient hospital episodes by identifying C3ch overnight service delivered :It an acuce c:\re ho!pjt.3.l for
which the rcimburscd Olmount W:\S greater than or equal to the
tI~u~iulc oa.UU\ult (\)1' (he cur"nc or pr,vious year.
OminltJon

0'

these CI1rOlleci iA both Mcdiccid cmd M.dic."\rt ("crouova-"

Regular Use of Other MedlcatJons
In additioo to the core drugs, we also identified 21 olher class~
of drugs c:ommonly us~d to treat chronic health problems. These
included other al;tnLS to CW\t c~rdiov1scular diseases (diuretic
ageno, beta-blocken, Other antlhypc:rtensive drug', and potassium supplements); or3l hypoglycemic agencs and diabeces.re.sring
supplies; psychoactive medications (anxiolytic, hypnotic. 3ntipsy:
chotic, and IUlcidepr~"o.nt drugo); nonccC'Tc:NdcJ. lu,ciin.Aa.mma.'Ory
:sgcnts, an~lgesies wich addictive potentbJ, and tnO$c used to
trest migu.inc; oral s[d'oids; and mediCcltions to trea.t ulcc:n,
thyroid disordet's. gl.1ucoma. P'lrJdnsonism, ~out. and chronic diarrh~. As :I. measure of b.1se-line comorbidiry, we counted the number of fhese 26 cbsses of drugs for which e:lch member of che study
groups received eight or more prescriptions in the tslle-Iine year

nablc I).

.

StandardIzation of Use of Study MedIcations

To tn.ck drug usc for the differenr study medicacioru, we: used
~sc-1ine data on the entire: Medic;aid populations of both Iltlltes to
create an inda of .standardized monlhly doses (Ot each of the core
me.(llcadons. One stand~rd dose equ!.lcd the medIan numbeT 01'
milligrams of active ingredient peT month received by all the patients who filed a claim for each study drug.

Statistical Analysis

I

I

.j'
, .1

Using SUMv!l1 analysis, we: meJsuf'td the rate of admission co
hospltals and numnS' homes In New H..l1npshire and N~ J~r3ey
during three periods: b.se line (April 1981 to August 1981), the c~p
(Septembcr 1981 toJuly 1982), and aftcr the cap (August 19B2 to

June J 983}.I7· 16 \Ve ~!;o weul;l.tcd

UlO

rWtlvc rick.: of inc:titutio.n~l

I'

I

:I!

I

Table 1. ease-Line Ch8r3cteristic~ of the Study and

Comparison Cohorts.
NI;UI'II.,C ..

NEW IiAWl'UlIIU!
STUDY CoHOkT

CIl .....aJ!'Clme

(N - 411)

COM"UI~O'"
COHOtT

eN" -

1J7S)

piA-

tier:us) had stable coverage for these: $uvices. PMienu w~re included
in d1c ,rudy if they had 10 Dr mcre mon[hs of enrollment in Medic..
Aid during tbe base-tine year truly J. 1980, to June !SO, 1981); were
60 years of ~ge or older and enrolled in Mcdicsrc by the Slut of the
payment cap; were white (to control for the ab,ence of nonwhite
patients in the New Hampshire cohort>; were living in the community at base line, wich no nursing home claims during (he t) months
.b~fore follow-up began; had an average of three or more prc:scriptions per month and at lcast one prescription per qus.rcc:r during the
b~'line YC<Ll' <&laY u~cJ aucdjuti,;>n for on(. or morc or hV1: major
chronic illnesses (dja~tes, heart disease, chronic: obmuctive pulmOllary disease and asthma, .seizures, or oondition.s requiring the .
1~~ or anti~2sul'nf") R,..,.:IIU:,. ,,"t~ti~nr (Ii.lenn..~ .._~ arr. often unrcllilble, 16 the reguJar n:ccip~ before the cap, of .m<:dicatio~ commonJ)' used. to treanhcse illnesses ~erved as markers for them. To eliminate occ~oD.1l uscn ot t.hc:se dru~, we defined rCg\liar users a.s
p.lticnrs receiving eight or more prescriptions in any caccgory of
'~rkcr mcdica(ion3 during the ~e-linc: yt:~r7 ~nd at least one per
,l.Ianct'.

A pane! of geriatricians, internists, and eUnlcaJ pharmacins identified !pecific classes of moarker mediations, including antiansinal
~S'S,loop diurC'tic agents, antiarrhythmic sgcnu, bronchodilalors,
'nhal~d Jceroid;, in~\alin, :ultico~l:'Ibntc, ~n.ci ::anticonvuL:~t :tsenu,

l;'
:
1".i1

hereafter referred to as the core drugs. Medications were cho~en for
w:u; Ji:ble to 'preeiplt~te iMtitutionaliution. Agents were excluded if they were frcquendy used for
noD targeted 3$ well AS tugt1cd iJlncs!.cs (e.g., bets-blockers are
indicated for both hypertension snd sn~na), had que:tionablc: efficacy. or were auociated with Jess serious Ic:vds of illness. Thu.s,
~hhough they l~d to. th~ c:xclusion of some p~tienu with targetc:d
t11nessc:s, the IUnct a"lteraa for regular drug use saved to increase the:
baso-line comparability of the study and companson cohorts.
ttudy if choir cuddcn wichdn.w:U

the Study Groups

The study groups represcnte<i a vulnerable, noninstilutjon~ized
popubtion of Medicaid palien" over the agc of 60 who were being
trea.ted for specific. chronic illnesses at base line. Patients without
Mcdlcarc coven.ge were Ctcludcd because in New H.lmpsblre, patients enrolled ollly in Mc:dicsid h3d limits on physicians' scrvicr.s
~d hospiul cbys in addi.tion to tbe cap on medications, whcre:.s

t

J073

".~(

Age (yr)

60-69

27
43

7~79

~80

30

Feln:de seJt
Rc!;ulw

II)C

80
vC ,",u'c;

medj'.ltiOlU
Cardisc
COPO ;.nd ::asthl1\ol-

77

aaulin

Amico" vuls.aa bi:.Antico~gl.tlsnts

19
16

86
15
9

6

7

I

2

Number of slIldy ~di.c31ions
~

reguwly1

J
2
;:'4
~I

21

46
33
80

Inplllienl epLsodCl during
6 mo before oap

·COPO dcnolC~ chro~ic:

ob!U\I(li""

16

12

36
30
18

32

1S

~s

27
ZJ

pulmonll)' 4i!CI~~O .

tThe CQ~ mediC::llja~ ,I,,~!he 21 alhcfcb::c:.: of dnop C~mr.lOl\ly u.~cd
'''' ,....:-.,

,.h~,.;~

"".11,. 1'''''...... ' ' C

;

I

izati~o and 95 percent two-sided (ont\dc:n~c

e

iUlC4 '0'0113

in the atudy

grO\lps.'t We used segmented time-series regression mc:>dels to esrimate changes in drug use, including a constant tc:rm, a linear time
tTend, and (CTm~ lV c;)linu.tc: chlU\sec \n the m~n ' ..vel of usc: or c:ore
drug1 during an "antici~(ory" pt'e~p monch (August 1981) and
,
during the cap and copayme1lt periods."

I

I

RESULTS

,

II

I
i

,J
!,

I

'I
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Background Characteristics of the Study Groups

After the cap W::f~ rp.placed by the $1 copaymc:nt, these

rates rose almost to base-line levels.
Effects on Nursing Home Admissions

The most clearly observable effect of the payment
in New Hampshire was an increase in nursing
home admissions (Fig. 1). The proportions of patients
entering nursing homes were similar in the study
s'roups before the: cap: 2.3 pe-Tf'"p.nt in New Hampshire
and 2.1 percent in New Jersey. After the institution of
the cap, there was a marked separation of the two
survival curves showing lhc probability of rCIn.ining
in the community; by the end of the II-month cap
r~p

The base-line demographic characteristics and
rates of drug use weTe similar in the New Hampshire
and New Jersey ' grOllp~ (Table 1). The hi,gh proportion of women in both cohorts (SO percent) reflects the
predominance of women in frail, elderly populations.
.. In the year before lllc c~p poli
cy was instituted, approximately
All Patients
four out of fivc patients in both
1.00
cohorts were regular recipients of
core medications indicated for
• New HampshIre
heart disease; rar,.~c; of regular use of
- 0 New Jersey
medications for chronic obstructive ,
0.95
pulmonary disease and asthma, diabe(es, am.l scizurC3 were all simiQ)
lar, as were rates of usc of anticoagE
o
ulant agents. The total number of
J:
classes of drugs taken regularly WCi!i
~ 0.90
slightly higher in the comparison
'iii
:s
rnhort; we controlled for the potenZ
tial effects of this difference through
I
the stratified analyses reported be1
~ 0.85
I
I
luw; Although patient-spec:ifir tlata.
.~
\
I
:::l
on income were unavailable, both
I
o
I
cohorts were very poor, with inI
0')
....
I
comeS substantially below federnl
.~ O. 80 '-'-.........J.-.L......I--LI--'-~~............-L.-.l--J-..J.-.J-,.IJ.......I..............I--I-...I--..L..-L....,.j.-"'--"-~
poveny levels; at the time of the
E
study, the monthly income of elQl
Palients Takin9 3 or More Classes of Drugs
a:
derly recipients of supplemental
I
I
a
I
security income who lived alone
w3.~ about 1'3.')0 in both states.'Zu
.~
:aca
During the follow-up period, simi~
lar proportions of patients (35
o
0:
0.95
percent in New Hamp:Jhire :u\d 28
percent in New Jersey) died or left
,~
(ij
the Medicaid program for other

l~

~-=
I

reasons.

;;

E

::I

Changes In the Use of Study

U

0.90

Medications

During the base-line year the
median n\lmhl":r of standardized

I
i

,I

monthly doses of core drugs per
month \'I-as stable at 2.8 in New
Hamp!ilti,lC: and 2.3 in New Jersey,
There was no change in the usc of
these agents in New Jersey during
the study period. in New Hampshire, however! the time series of
drug 1I~P. dropped by 35 percent, to
1.9 standardized monthly doses per
patient per month after the cap was

instituted (two-~ided P<O Of) 1) .

I! ' "
i

O.BS

Base Lim:!

$1 Copayment

Cap

Periori
F'lQure 1. Cumulative Probability of Remaining outside a Nursing Horne.
Tho top panel show~ the curves for all patients in the New Hampshire (n = 411) an

New Jersey (n = 1375) groups. The bottom panel shows the curves for patlenl~ wh
regularly used drugs from three or more classes at base line (n :. 198 for New
Hampshire and 762 for New Jersey).
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period, 10.6 percent of the New Hamps.hire patients
and 6.6 percent of the New Jersey patients had been
admitted to nursing homes. The difference between
. the two survival curves during this period was signifi~
cant (two-sided P = 0.006), and the relative risk of
admission associated with the cap was 1.8 (95 percent
confide.nce intervnl, 1.2 to 2.6). After the cap poli~y
was discontinued, the use of CQI'e drugs returned al.
mos t to precap levels and the excess risk of new admisSIons to nursing homes ceased, as evidenced by the
approximately parallel curves.
Further analyses were stratified according to the
proxy variable for comorbidity (the regular us~ of S or
more of the 26 classes of drugs). Again, the rates
of nurcing home admicsion in the two ~tates were
similar before the cap began and afttr it was replaced
with the S1 copayment (Fig. 1). During the Period
of the cap, however, the excess risk of admission
to a nursing home was even greater for these sicker
patients in the study cohort, more than double Ule
rate in the comparison cohort (relative risk = 2.2;
95 percent confidence interval, 1.2 to 4.1; two-sided
P ;:::: o .on04) Ry the- end of the cap period, ~n estimated 14.4 percent of New Hampshire patients regularly
taking drugs from three or mO.re classes had entered
uwsing homes, ~ c.ompa!cJ wilh unly 0.2 percenc of
such patients in New Jersey. For the patients taking
drugs from fewer than 3 of the 26 drug classes there
was no significant ditlerence between the study and
;omparison cohorts, indicating that the cap's adverse
effect was most pronounced for the patients who wefl~
most disabled.
'A'e next investigated whether this loss of independence tended to be perma.nent or temporary. Figure:. 2
shows trends in the proportions of patients residing in
nursing homes in (he two study groups. All the palients were included in this analysis until they died or
became permanently ineligible. The data indicate that
nursing home stays were not short-tenn. After the cap
was instituted1 there was a steady rise in the propor~
tion of New Hampshire patients in nursing homes that
pen:i~tl"'ti lJntil thp. end of the cap pE:riod. By then, 7.7'

• New Hampshire
o New Jersey

Per10a
F'9ure 2. Monthly Proportions of Study Patients Residing in
Nu~lng Hom9~.

The :urves include all New Hampshire (n : 411) all(j New Jersey
(n = 1375) patients.

~ .

1075

0')
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Q)
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• New Hampshire
o New JGtsey

(5

Z
o~
.?;-CP

=~
..0'"
CIJ~
.aU)

a:° 0l:

I
I

0.7

I

0.6

4)

.~

7a

'3

E
~

o

Period
Figure 3. Cumulative Probability of Not Being Hospitalized.
The curves include the New Hampshire (n = 19B) and New Jersey (n = 762) patients wno regularly used drugs from U'lree or
more classes at base line.

percent of the 325 remaining New Hampshire patients
were institutionalized, as compared with 4.4 percent
of the 1147 New Jcr3CY patients, cy"Cn thou~ll tIle lime
series was approxima.tely parallel before initiation· of
the cap and after its abandonmcnr.
'Vv"e also calculated the distribution of 1cngths of
stay among the New Hampshire patients who entered
nursing homes (ri = 4-6). Among the 37 patients who
entered nursing homes just before or during the period
of the cap (for whom 12 or more months of follow-up
wp.r~ av::tibble until the end of obcerv~tion), 32 percent stayed for 6 months or less and 57 percent had
stayed for 1 year or more; 90 percent of the long-term
Te~idclHs wen: :iull in nursing homes during the final
month of observation.
EHcot~ on Hospital

I

I,
I,

l
I:

Adml6Slons.

Analyses of time to first inpatient hospital episode
were similarly stratifi~rf arroTding to thc number of
classes of drugs (he patients toak regularly. Patients
who regularly used drugs from three or more classes
had eompl.ro.bJc rates of hq3pitali1;i).ciou. Lcfvl c U1C c;ap
was instituted (Fig. 3) . .After the introduction .of [he
cap, there was a moderate trend toward increased hos~
pitalization amoogthe New Hampshire patients that
did not reach statistical significance (relative risk =
1.2; 95 percent confidenc~ intcrval, O.R fo I h); this:
trend disappear~d when the cap was replaced with the
Sl copayment policy (Fig. 3). No increased risk of
hospit.ui:Z4l.tion:. W'3~ found in the patients who u!scJ
drugs from few~r than three classes before the cap .
"DISCUSSION

Although quasi~experimcntal evaluations of policy
changes can never provide ironclad evidence of caw:eand-effect relations, our results provide strong indications of a direct relation between the introduction of a
rhrf'r.drug reimbursement limit, 3. re~ulting reduction
in the use of medications, and an approximate doubling of the rate of nursing horne admissions among

· 1·

I
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I

chronically ill elderly }JC1licnts. Rates of :a.dmission to
nursing homes among the study and comparison cohorts were similar before the: cap was instituted, diverged soon after its introduction, wh<:n the u::;c of
medications declined, and once again became similar
aftcr the cap W;lS abanclonp.d. These effects were concentrated among patients who regularly used three or
more study medications, indicating heightened vulnerability among patic:ut..:s with more thQn one chronic
illness. A separate, ongoing analysis in New Hampshire also indicates an association between the rate of
reduction in drug usc due to the cap and the ri.sk uf
institutionalization (data not shown).
Were nu.rsing horn,. ;\rfmissions caused by declining
health or by the desire to maintain the use of essential
me:dications, because the: three--drug limit did not ap. ply in long-Lc:ru.l care: faciliti~? Since admission r~~
ords were not available for this study, we could not
distinguish between these two mechanisms of effect.
The increase in nursing home admissioIls 4ullong the
padents at highest risk suggests that the loss of medications conln have exacerbated preeXisting medical
problems. However, because patients are ofcen admitted to nursing homes without e~lier hospitalizaLiuu," and given ca.£c reports by Nf':W Hampshire
Legal Assistance of several patients who were transferred to nursing homes to avoid the policy's dIect, the
cap probably precipitatc:<l UU1SU'lS' home: admi&&ion&
for financial reasons as well. Regardless of which
mechanism eJ(plained the excess admissions, the economic impact of prevenrable institutionalization and
its effects on quality of life are severe.
Although we oh~~rvf':d a slighe trend roward increased hospi(alizarion during the period of the cap,
the absence of a significant effect on rates of hospitalizacion dC:iCJVC5 con'lmcnt. Incre.3.~e! in 'the: rtlt~ of h()~
pitalization may have been too low to be measured
against the high background rate in a chronically ill
population. In addition, the me~ure used (ljlllC to
first hospital episode) is insensitive to changes in the
rates of rppeated events; we unfortunately did not
have access to data from the primary payer for hospital scrvices, Medicare, which would have allowed
lilUt..-:scl'ic.s MalY3e:J of

.,
I

I:
I: I,

~l

;Ldmiss:wns

The study and comparison cohorts were well
matched at base line for patterns of drug use, soc, and
race, as well as nursing home: ant.! InJ;;pital U3C. The
New Jersey cohort was slightly older and received
more reguJar medications than thc New Hampshire
group, but this would be expected to reduce observed
differences in outcomes. All the patients rccei\'edmore
than 36 pre&criptions in tnl" hase-line yt:ar. a rate of
medication use strongly associated . with fair-to-poor
health in an earlier national study of Medicare beneficianes. 22 The increase in llll:: 1 acc of cntry into nUTl~ins
homes immediately after the initiation of the cap
makes it less likely that differences in the patients'
characteristics were responsible loe these effects.
It is unlikely that other changes in policy influenced
the observed ch~ne~s in the rates of institutionalization. A potential confounder would have had co begin

I.

I

\,.
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the initiation of (he cap and end at its termination,
which is improbable. Since all the study patients were
eligible for Medicare, they were exempt from the limiu on ho~pit3.1 and physlri~n~' services imposed on.
non-Medicare patients in New Hampshire during the
cap period. Changes in the supply of beds might influence the rate of admission to nursillg hOlllC3. 2J How.
ever, the supply of nursing home beds per 1000 elderly
r~oplc in New Hampshire actually declined by 3.5
percent from 1981 to 1982, the period during 'W ruch we
observed increases in the rates of admission as com;tr

pared with those in New J~r~t'.y.Z3
Previous studies have indicated that the New Jersey

diagnosis-related-group program initiated in 1980
probably caused a sHghr decline iu length of stay and
a small increase of 0.8 percent per year in hospital
admission rates. a The program, if it had any effect at
all, wouJd thus have shortened t~e time to first hospital admission slightly in the comparison cohort, resulting in 3. smaller rehtivp difference between the two
cohorts.
At present, about one fourth of state ~redicaid programs have limirs on Ul U!:, reimbursement in effect.
Our findings raise questions about the clinical and
economic wisdom of such policies. Our best estimate
of the excess person-months of nursing home usc jll
thc study cohort equals the difference between the proportiCln~ of the two study groups res..lding in nursing
homes each month. During the 22-month observation
period after the cap was instituted this excess was
cs(j1ll4lcd to be 1 it pel·!:on-months. rviw~n New
Hampshire Medicaid's daily reimbursement rate of
$59 in fiscal year 1982-1983 (the average of the rate~
for skilled-nursmg facilities and intc:,nut:uiatc-carc fa
cilities),2:i chese excess months in nursing homes COS 1
$310,745. This underestimates the true cosc, since il
docs not include other incremental expenses (e.g.
physicians' services) and it assumes no months ir
nuraing homes beyond tht": (')h~p.rvation period. Addi
tional increases in hospital and nursing home admissions in other vulnerable populations that we die
not study (e.g., the: ciuuui,ally mCnt~lly ill) coul,
raise such unintended costs well over the estimatec
statewide savings of 5300,000 to $400,000 achieVe<
by the cap. II
Changes in health care reimoorsemcnt policies hav
probably had si7:\hl~ p.ffccts on elderly and low-in
come patients OVC1" the past decade, but objective dat.
on their elTects on quality of care are extremely limit
ed. J:hc c.h iilkugc for rcscarchet':J ;)nd policy rnalc.~l"C; i
to discover which cost-containment methods are mo~
"efficicnt
reducing ineffective care ....'hile preservin
access to forms of medical technolOgy chit l Lend.
both individual pacienrs and socicty as a whole.
We a~ illucLLcd to Diln Cilden, director at J~N ".;~oci.ltes. r,
1

in

!ltati9tical and dal.\ processing support; (0 flin Griesba~h for c1
coding :lJld graphic present:ltion of da.ta; to Jerry Gurwlt%, M.l:
s.ndJonn Fol,.y. Ph:um.D .. for excellent clinic~ ~dvjct; [0 Dr, s~
phcn L.lg:\kos for importanc ins.ighrs into rhe ~trucruring 01 t.'
stati~tic~1 30illy:tis; to the officers and staff of [he N~ fumpsh 1
and. Ne:w Jersey Mcdiclid programs who supplied the dau; .1n~
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Industry Headache
States Square Off
Against Drug Firms
In Crusade on Prices
~Iichigan's

Ne\v Experiment.
Leads Pfizer and Others :
To Stage a Boycott

Vioxx Doesn't ~Iake the Cut
Efforts by state governments to cut prescription-drug prices are sweeping across
the nation, posing a serious challenge to
the U.S. pharmaceutical industry's mighty
lobbying machine-and to its profits.
This summer, Florida announced that
. drug companies participating in its lucrative Medicaid program would need to provide special rebates. Maine restricted ~led
icaid access to expensive drugs while separately threatening companies with price
controls if they didn't offer discounts to
residents who don't have drug coverage.
And this morning, Michigan plans to release a list of lower-cost drugs whose
prices other drug companies. must match
in order to receive preferentIal treatment
from state drug programs.
Pharmaceutical companies are fighting back with lawsuits and adverti~in~
campaigns, and rushing to sta~p out ~lml
lar movements in Louisiana. ~llssoun, In- .
diana and ~Iaryland.
But some in the industry say the number
of cost-cuttinastates may be reaching acritical mass. "Alone. they can be picked off,
but if they stand together, they can win,"
says Diane Rowland,
executive director of
the Kaiser Commission on Medicaid and
the Uninsured, a Washington-based healthpolicy think tank.
At stake are potentially billions of dollars in sales, not just
to states and publicaid programs but also
John Engler
to the private healthinsurance market. which often is influ-.
enced by new developments in state pol- :
icy. Equally worrisome to the industry, the :
latest developments signal that the battle :
has shifted away from Washington-where
phannaceutical giants have cultiv~ted
great influence -and to state capItals
around the country. where it can be
harder to fight back.
.
Surprisingly, the most ~amagmg 5alvOS
haven ' tcome from regulatlOn-nunded Dem-

ocrats but influential Republican governors
with close ties to the White House. including
the president's brother. Florida Gov. Jeb
Bush. and ~1ichigan' s Gov. John Engler.

"The political wtnds have changed,"
says Arkansas' Medicaid director. Ray
Hanley, who personally helps speed the
change by passing word of new developments with a flurry of e-mails to his colleagues. ''I've got all 50 Medicaid directors
on one button," he says.
Adds Michigan's Gov. Engler: "Michigan will be a Signal for other states and
other states will follow."
The changing climate began as the
economy sputtered early in the Bush administration, drying up states' tax revenues, This forced them to confront the escalating cost of pharmaceutical drugs under Medicaid, a federal- and state-funded
health plan for the poor and disabled.
States collectively are forecast to spend
around S2S billion buying Medicaid drugs
during the current fiscal year. Last year
their purchases represented about 12Qc of
total industry sales.
States were also disappointed when
Congress failed to pass a prescription-

By Wall Street .Journal staff reporters
Russell Gold in Lansing. Mich., Scott
Hensley in Nelc York and Andr~u.:
Caffrey in Boston.
drug benefit in :\Iedicare, a health plan for
the elderly. While the states don't help foot
the :\Iedicare bill, as they do with ~ledic
aid, most have programs to help the elderly pay for their prescriptions. For states.
pharmaceutical drugs were no longer _~
footnote in their budgets; they were
quickly becoming a major line item.
In July, Florida became the first state
since federal Medicaid laws were overhauled in 1990 to extract additional price
concessions from drug makers. Under federal law, pharmaceutical companies that
sell to state Medicaid programs must offer
them the same prices they give their mostfavored customers. Florida took this a step
further, generally requiring companies to '
offer rebates averaging around SC:c on top
of those already-discounted prices.
:\Iichigan's experiment is potentially
even more serious, because it expands
well beyond ~Iedicaid-funded drugs, and
because it takes dead aim at drug companies' freedom to set prices. Instead of taking as a starting point the prices offered to
companies' most-favored customers, the
~lichigan experiment seeks to drive all
prices down to a low common denominator. A similar movement in Europe, known
as "ref-erence pricing," has savaged drugcompany profits there.
In :\[ichigan. it works like this: A committee of 11 doctors and pharmacists,
meeting privately in a windowless basement conference room. chose so-called
"best-in-class" drugs in -to categories that
would get special treatment in the S1.1
billion the state spends each year on prescription medicines.
The selected drugs will be guaranteed
a handsome slice or the state expenditures
in both :\ledicaid and J state-funded proP' r'([SI:! T ~lI'?1
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States Clash With Drug Industry
Over Price Controls
Continued From First Page

gram for the elderly. Doctors can prescribe drugs that aren't on the list but only
after justifying their decision in a call to a
phone bank of pharmacy technicians - a
requirement expected to discourage use of
those drugs. Thus, all companies wanting
to sell drugs under these programs risk
losing market share unless they agree to
slash prices to also win a spot on the preferred list.
An early preview of the list shows that
several of the biggest drug makers will be
hit hard. Among pain relievers commonly
prescribed for arthritis, for instance, generic ibuprofen and generic naproxen
made the preferred grade, while the
widely prescribed . Celebrex, jointly marketed by Pfizer Inc. and Pharmacia Corp.,
and Vioxx from Merck & Co. didn't.
Although the state won't detail the p0tential savings, they appear to be large.
According to Fred Ghannam, owner of
Capitol PhaI1Ilacy, about one block from
the state capitol building in Lansing. the
retail price of a month's supply of generic
prescription-strength naproxen is around
521, while a comparable prescription for
Celebrex is $151.
Lumping the Old and the New
Drug makers complain that the program is flawed because bureaucrats lump
old and new drugs together, declaring all
medicines in a given category to be equivalent. This thwarts industry efforts to differentiate their newest wares-and, they say,
gives them little incentive to spend money
on research and development.
The industry's counterattack has been
swift. Last Friday its trade association
filed suit-the group's fourth against a
state government in the past 16
months-seeking to block the Michigan
program, scheduled to go into force in January. Meanwhile, six major drug companies refused to play by Michigan's new
rules, declining to make any price concessions to guarantee a spot on the state's
preferred list, or fOI1Ilulary, for those
drugs not selected best in their class.
"We think they've gone too far," says
Charles Hardwick, a senior vice president
for government affairs at New York-based
Pfizer, the world's largest phaI1Ilaceutical
company, which declined to participate in
the Michigan price-cutting program;
Early results from other states that
have adopted programs less restrictive
than Michigan's show both the potential
upside for states and possible downside for
companies that don't cut prices to get on
the states' preferred lists of drugs.
.
Florida expects to save at least S100
million this fiscal year. At the same time,
sales to ~Iedicaid of several drugs not on
Florida's preferred list have plummeted:
The market share of AstraZeneca's heartburn drug Prilosec in Florida dropped to -1%
from 38% in the first three months since the
preferred list went into effect, while Pre-

vacid, from TAP Pharmaceutical Products
Inc., Lake Forest, Ill., saw its share rise to
65% from 43% over the same period.
Drug companies worry that doctors out
of sheer habit will be more likely to prescribe Medicaid-preferred drugs to their
non-Medicaid patients, as well. At Miller
Drug of Bangor, Maine, which fills more
than 1,000 preSCriptions per day, phaI1Ilacists say they're seeing just such a trend.
For instance, after Maine selected Madison, N.J.-based American Home Products
Corp.'s Protonix as its preferred heartburn drug beginning this year, the medicine was dispensed for nearly 75% of Miller's Medicaid heartburn prescriptions, up
from just 3% three quarters before. There
was a smaller but still-noticeable increase for the rest of Miller's customers. Protonix
was the dispensed drug for 13% of heartburn prescriptions, up from 3%.
The industry is fighting back most vigorously in the courtroom. As MiChigan officials were developing their plan, the Pharmaceutical Research and Manufacturers
of America, the Washington-based industry association known as PhRMA, filed a
lawsuit against Florida in federal court in
Tallahassee. The group argued that federal law allows states to limit access to
Medicaid drugs only if they offer no clinical benefit, not if the manufacturer
doesn't offer a large enough price cut. A
hearing is scheduled for today.
"The state litigation is unique to the
last few years, because states are becoming more aggressive in trying to regulate
pharmaceutical prices," says PhRMA assistant general counsel Marjorie Powell.
So far, PhRMA has won only one
case - killing a Vermont effort to use Medicaid to provide drug coverage for noneligible seniors. But the suits have had a chilling effect. Iowa and California are launching efforts to get drug companies to voluntarily offer discounts to seniors, partly because mandatory price-cut programs have
sparked industry lawsuits. "If someone litigates-rightly or wrongly-it puts a stop
to what you're dOing. YO.U cannot move
forward," says Dr. Carol Kuhle, chairwoman of the nonprofit corporation Iowa
created'to run its new program.
The industry was slow to marshal
forces to fight the Michigan program because state officials deliberately concealed
what they:were up to for several months,
Faced with Medicaid and other statefunded drug costs that doubled to S1.1 billion over the past two years, state health
officials needed to find 542 million to plug
a hole in their new budget and find some
way to control escalating pharmaceutical
costs long term. James Haveman, director
of the community health department,
which runs Medicaid. was convinced that
~Iaine and Florida were heading in the
right direction but wanted to go farther.
In June, he proposed to state lawmakers that the mandated price cuts be expanded beyond ~Iedicaid to also cover the

.~I

state's senior drug-assistance program
and other state-funded programs. But
state Rep. Mickey Mortimer, chairman of
a subcommittee handling this piece of the
budget, balked. "I wanted to be sure we
didn't put anybody at risk," he says, worried that patients would be denied access
to needed drugs_

Novel Approach
With the budget at a standstill, Gov.
Engler intervened, calling Mr. Mortimer
and other top lawmakers to his office. Mr.
Engler suggested a novel approach: pass a
budget with broad language authorizing
unspecified phannacy practice changes by
the end of September. In the meantime,
state health officials would develop the specifics of the program. If Mr. Mortimer or
his counterpart in the state senate didn't
both like the resulting program, they
would have a chance to block it. Within
five minutes, a deal was struck.
During the three months he had to develop a plan, Mr. Haveman decided he
didn't want to be slowed down by pharmaceutical companies applying lobbying pressure. He instructed his top deputies not to
meet with or take phone calls from drug
makers.'
"I needed time to think and plan," says
Mr. Haveman.
It was another lesson learned from
other states, where intense industry lobbying had killed drug-rebate proposals. "The
states have learned that if they are going
to be able to negotiate deals and work
against the drug companies, they have to
do it behind closed doors," says Ms. Rowland of the Kaiser Commission. "If they do
it in too open a way, they will be lobbied to
death:'
Industry officials were livid. "This was
handled with speed and deception, " says
Stephen Scofes, the Lansing-based lobbyist for Eli Lilly & Co., Indianapolis, and
Merck, who tried unsuccessfully to schedule a meeting with Mr. Haveman.
On Sept. 28, two days before the deadline imposed by the state budget, state
health-department officials disclosed how
its preferred list would be put together.
Mindful that Florida's program had been
sued by PhRMA for basing its list mainly on
discounts offered by drug makers, Michi-

gan's lawyers suggested a different approach: Acommittee would justify its decisions based on clinical grounds. During
three meetings, the committee scoured scientific journals and debated the benefits of
drugs in 40 categories that account for the
vast majority of state drug expenditures.
In early October, First Health Services
Corp., a suburban Richmond-based subsidiary of First Health Group Corp., Downers
Grove, Ill., contracted by the state to ad- minister its pharmacy program, invited
the companies to meetings in Richmond,
Dallas and Lansing to tell them what discounts they would have to provide for their
drugs to gain preferred status.
Drug companies say they were left in
the dark during the crucial process that
defined the categories of drugs and selected the so-called best-in-class drugs .
"When we met with First Health Services,
we discovered that, in fact, none of the
terms of the agreements were open to negotiation," David Marin, an vice president
for at Peapack, N.J.-based Pharmacia
Corp., later wrote to state officials.
On Nov. 13, the day before lawmakers
gave their final approval, Merck advised
the state it would refuse to offer any rebates. Pfizer, Eli Lilly, Phannacia, Johnson
& Johnson, New Brunswick, N.J.; and Wyeth-Ayerst Laboratories, a unit of American
Home Products, quickly followed.
On Nov. 30, PhRMA filed its lawsuit in
state court.in Lansing, alleging the way in
which Michigan adopted the program violated the state constitution and state laws.
Both sides are taking risks. The six
boycotting drug companies stand to lose
market share to competitors that agreed to
cut prices to get on the state's preferred
list. But if doctors or patients balk because
some of the six firms' most-prescribed
drugs aren't included, that could force
Michigan to back away from its program.
Whicheve~, side prevails, says Arkansas' Mr. Hanley, other states are watching
the battle closely, to help plot their next
move. "If a huge state like Michigan can't
do this, then smaller states like us probably can't either," he says. "I'm pulling for
Michigan."

A4

THE \WLl" L STHEc"r .JO{)ltNAL TVE:::iDAY. Jfu\lU.\r"Y ~. lull:!

===:==I================:============d

Injunction Blocks Michigan ~Iedicine Law
BI,'
Se(vf

: ~ ill:;~l,:t.ll

RCp'.rc~,. "."

Go(.n

"'" W"t.' :)"I~I'~"

JO\ ;I,N ,'.

In (l victo'~ lor the pharmaceuticals
inclust:-/. a 1\1 ich:llan judge yesterdJY is·
sued a prelinlirl'~;'Y mjunction to block ()
stace l:-..w th ;t t ,'leeks price concessIons
tram drug cc,'nl'i.l lies in exchange lor In·
cJusior. on 11 1 s:, (,f preferred drugs,
The lawsu't V"I~S med by the Pharma·
ceutlcn,l Rese;~rrl ' and McinUrd.cturers of
AmericJ.. a W~ll ngton trade group. The
group. knowlI 0: PhRMA, orposes the
gt'owing numl: el' r f stlte efforts to restrict
access to prc~ c'illtion cJru~s as a way to
control risIng h ~;.\\th·c(\rc costs.
Under the [Ir>l')sed Michig,\n progrnm.
doctors must ca.lll,) seek permission to prescnbe drugs thil r I~ren 't on the slate's pre·
ferred .:i1'Ug list . ~f!' le preferred·drug law covers 1.6 ~llllon 'lE (. IIle in Medicaid and other
state,!u:lded tlchU: 1 programs.
In his order g' '~1I1tini the Injunction. Ing·
ham Countv C X,:\I; t Court Jl!dge Lawrence
M. G!a;:~r r\.:l, d II. Jt the unorthodOx mannero! Ir."'.plemt~nllig the Michigan lllw-scv,
ern.: prcr.1inem I ~';Iisl~tors were glven what
a.moun~~d co l~ v~~lto over the pollcy after
Gov. Jchn En~~ler ::rgncd the l«w-violjt~d
the st,\.~e conSI it ullion. The judge ;'llso was
pers\la~~cl b~1 ~'r'lIliments trom scverJI
gToups :-~presl:ni' ~ the mentally ill thaC restrictir.;; a:ce~ ; lo,:ertJin drugs could Ilium
patients. The j .1(11~·!~ l:!ltowed those group.:i to
jam the lc\wsul t.
The :'.tichiF'nn IDep:l.rrm~nt of Commu·
nity He=.lth ha 'i :1I:!d Iln emergency appeal
to the srl.tc ~pr ~~ ' lIt\tc court a.nd hopes to "
stil! be able to ITHI'i ,ement the prerelTed list
,
on Jan. l~. a~ rl:.h1ned.
Thp state's )rc,('!rred·dnli list W,\S devel·
oped by a coml"l :"1 e of physicians and ph~lr'
macis rs who m1~t lil,;t (nn to select It least two
"best·in-class'· d:"I~s in 40 diCfcrent c~tcgo·

ries. These drug:; '.."ould go on the preferred
list. Alt ~rherdrul=~· ,.vould mllke the ::>referred
ltst onlv tC the n a -.(I :· S cut theirpl'ices to equal
the :owe~t-pt1c, d "Ilest" dru~. Several compa-
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nics. indllcting Ptilt'r Inc. amI Mer!:\( &.: Co.
l'efusccllo offer any price breaks.
The Michigan decisIon comes just d.1Ys
after a federal Jl1dge let stand J. simllar
program implemented last yenr in FlorIda. Alrea.dy, other states seeking budget
savings are hoping to copy FlorIda, This
week Colorado l~wmJ.kers plan to intro·
duce a bill, modeled on Florida's program.
to seck additional rebates Cor Medicaid
drugs. TIle bill's spensor, Sen. Penfield
Tate. Suys he WIlS encouro.ged by the Flor·
ida !ederal-court rullng. PhRMA has appealed tile Florllhl Clse to the Eleventh
U.S. Circuit Court or Appeals in Atlanta.
PhR),{A W:lS pleilsed with the Mlchig:l.n
ruling. Jan Faiks, assistant general counsel
for PhR..'AA. says the prererred·drug' list \s
harmful because it interferes with doctors'
freedom to prescribe whac they feel is the
-
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most ilnpropriltc dru~, "The st:ile impos0d
Itself between the patient and the doctor."
she says, "We thinl{ thilt Is of tremendous po·
tentlal harm to the doctor·patient relation·
ship and ultimately to lhe pltien('s health,"
Mark Reinsteln, vice president of the
Mental H~alth Association in Michigan.
one of the groups which joined the la\llstli~.
says the preferred list "was set up to de·
prive tham {persons with mental ll1nes:J
or access to certain drugs and that would
hurt too many people." Geralyn Lash~r. a spokeswoman for
the Michigan Dep~rtment of Community
Health. says if doctors want to prescribl? :t
certclin dru~, tIle state llW doesn't StOP
them. It just requires an extra effort. "If a
drug' is medically necessary, that is thr!
drug a reCipient will get." Ms, LJ.sher
says. Michigan expected to Solve )42 mil·
lion this fiscal year from the prog1'lm,
•
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Senior groups square off over Medicaid prescription program
By DEE-ANN DURBIN
03112/2002
Associated Press N ewswires
Copyright 2002. The Associated Press. All Rights Reserved.
LANSING, Mich. (AP) - Senior advocacy groups are taking opposite sides in the battle over the
state's new prescription program for low-income patients.
The new state program, which took effect Feb. 1, allows doctors to prescribe only certain
discounted medications to the 1.6 million patients who rely on Medicaid unless the doctors get state
authorization for medications not on the list. The state expects to save around $42 million this year
with the program.
The Seniors Coalition, which has around 30,000 members in Michigan, came to the Capitol
Tuesday to present lawmakers with a banner covered with signatures of seniors who oppose the
prescription drug plan. Flora Green, the Seniors Coalition's national spokeswoman, said the
program could hann seniors.
"The doctor-and-patient relationship has to be protected at all costs," said Green, 79, who lives in
Utah. "How can someone who doesn't know me make a decision that supersedes my doctor?"
On the other side of the issue is the Michigan AARP, which has around 1.4 million Michigan
members aged 50 and older. The AARP supports the program because it says the state must control
prescription drug costs, which have reached $1 billion per year.
"Prescription drug prices can be prohibitively expensive to those without drug coverage, and older
persons tend to use more medications," Michigan AARP director Stephen Gools said in a news
release.
"We believe the Michigan program is a sincere, effective attempt to insure that that state has the
funds to provide prescription drugs to Medicaid recipients."
Green said she understood the need to control costs, but said the state should look for other ways to
cut funding.
"Does anyone have the right to balance the budget on the backs of seniors?" she said.
The program is being challenged in court by a coalition of drug companies and mental health
advocates. The Michigan Court of Appeals is expected to rule this spring on whether the program
should remain in place. Both the Seniors Coalition and the AARP have filed briefs in that case.
Meanwhile, state Sen. John Schwarz, R-Battle Creek, is sponsoring legislation that would require
the state to place practicing physicians, phannacists, drug company representatives and a patient
advocate on the committee that decides which drugs are on the state list.
Gov. John Engler appointed the current members of that committee last fall without consulting the
full Legislature. Drug companies weren't involved in the process.
"I question the wisdom of the present system," Schwarz said. "I believe it's really quite arbitrary."
But Schwarz, who is a surgeon, said he does support having a state list and requiring doctors to get
pennission before prescribing some drugs. Most health maintenance organj'?:ations have similar lists
as a cost-saving n1easure, he said.
On the Net:
The Senior Coalition, http://www.senior.org
AARP, http://www.aarp.org
Michigan Department of Community Health, http://www.mdch.state.mi.us
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Many on Medicaid Lack Drugs, Study Says
By ROBERT PEAR
WASHINGTON, April 8 - States have become so aggressive in trying to control
Medicaid spending on prescription drugs that many Medicaid recipients do not get all the
drugs prescribed for them, researchers said today.
Although Medicaid covers prescription medicines in every state, one-fourth of patients
enrolled in the program reported that they could not afford to fill some of their
prescriptions in the last year, the researchers said. In an environment of rapidly rising
drug prices, they said, states' cost-control efforts were the leading factor.
Most states are experiencing fiscal problems, and drug spending for Medicaid recipients
has been rising 15 percent to 20 percent a year. So state officials have adopted numerous
measures to rein in costs - some of them requiring co-payments, for instance, others
limiting the number of each patient's prescriptions.
"It appears that a consequence of aggressive cost-control policies is a reduction in
beneficiary access to prescription drugs," said the researchers, from the nonpartisan
Center for Studying Health System Change, who were led by Peter 1. Cunningham.
The study was based on a survey of 39,000 adults, including nearly 1,800 on Medicaid.
By most measures, it said, Medicaid recipients and people with private insurance have
similar access to medical care. But, it said, prescription drugs appear to be an exception;
some Medicaid recipients have almost as much difficulty as the uninsured in obtaining
medications.
Twenty-six percent of Medicaid beneficiaries ages 18 to 64 reported that they could not
afford to get all their prescriptions filled in the last year, the report said. That was just
slightly less than the 29 percent of uninsured people who reported similar difficulty.
By contrast, 8 percent of people with employer-sponsored health coverage and 8 percent
of elderly people with Medicare said costs prevented them from obtaining medicines.
(Medicare generally does not cover prescription drugs outside the hosnital, but about
two-thirds of Medicare beneficiaries have drug coverage from other sources.)
Len M. Nichols, vice president of the Center for Studying Health System Change, said,
"The findings are surprising because Medicaid is expected to ensure access to affordable
care for the poorest and sickest Americans."
Medicaid is financed jointly by the federal government and the states. The states have
broad discretion to decide on the details of their individual programs, within federal
guidelines, and all have chosen to cover prescription drugs. Having made that choice,
states must cover most drugs that have been approved by the Food and Drug
Administration. They cannot arbitrarily refuse to cover drugs for a particular illness.

Cost-control methods vary by state. Some states charge a co-payment of $1 to $3 for each
prescription. Some limit the number of prescriptions, allowing no more than three to six
in a month. Some require doctors to get authorization before prescribiflg certain drugs.
Some require the substitution of generic drugs for brand-name medicines, or require
doctors to try lower-cost drugs before prescribing more costly ones.
But Ray Hanley, the Medicaid director in Arkansas, which requires co-payments, said he
found it hard to believe that people were going without prescription drugs because of cost
controls. "If anything," Mr. Hanley said, "the co-payments need to be higher. The limits
on co-payments have not changed in 20 years, and many people, including children and
pregnant women, are exempt from co-payments."
Joan Henneberry, a health policy expert at the National Governors' Association, said:
"There's no question that cost-containment measures affect access to prescription drugs,
but that may be a positive outcome. We know that Medicaid beneficiaries are often
getting too many medications, duplicative medications from various doctors and, in some
cases, medications that are contraindicated and dangerous."
Some of the cost-control techniques used by Medicaid are also used by private insurers.
But Mr. Cunningham, the lead author of the new study, said these measures were more
likely to curtail access to prescription drugs among Medicaid recipients because they had
lower incomes and were more likely to have chronic illnesses. About 40 percent of
Medicaid recipients with two or more chronic ailments reported that they could not afford
prescription drugs that they needed, the study said.
No cost-control technique by itself severely impaired access to prescription drugs, the
study said. But a combination of such techniques made it more likely that Medicaid
recipients would be unable to afford medicines, it said.
In states with four or five cost-control techniques, an average of33 percent of Medicaid
recipients reported that costs kept them from filling son1e prescriptions, the study said.
By contrast, 15 percent of beneficiaries said they had trouble filling prescriptions in states
using one cost-control technique, or none.
The states with four or five cost-control measures, the report said, are Arkansas, North
Carolina, South Carolina and West Virginia.

Issue
Brief
Findings from HSC
PRESCRIPTION DRUG
ACCESS: NOT JUST A
MEDICARE PROBLEM

While all state Medicaid programs provide outpatient prescription drug coverage,
slightly more than one in four Medicaid patients ages 18-64 could not afford to fiU
at least one prescription in the last year, according to a new study by the Center for
Studying Health System Change (HSC). A similar percentage of uninsured adults

by Peter J. Cunningham

also had difficulty affording prescription medications. Faced with rapidly rising
drug spending, many states have moved to control Medicaid prescription drug
spending by imposing copayments, limiting the number ofprescriptions and using
other cost-containment methods. The study indicates that these state cost-control
measures are contributing to Medicaid beneficiaries' prescription drug access problems. State and federal policy makers should keep in mind that the impact of these
controls on Medicaid beneficiaries is likely to be greater than on privately insured
people, given their higher need and lower incomes. 1

Nonelderly Have Problems AHording Drugs
~ hile

recent federal and state policy

'II debates have focused on the prescription drug needs of the elderly in
Medicare, many nonelderly adults also
have problems affording prescription
medications. According to HSC's
2000-01 Community Tracking Study
Household Survey, non elderly adults
enrolled in Medicaid and those who
are uninsured have the most problems
affording prescription drugs--more
than one out of four people in both
groups did not get at least one prescription drug in the past year due
to the cost. This is in sharp contrast
to those in Medicare and those with
employer-sponsored private insurance
(see Figure 1).
CENTER

for STUDYING

HEALTH
SYSTEM
CHANGE

The fact that adults with Medicaid
coverage have problems affording prescription drugs is surprising. Medicaid
is designed to ensure access to affordable medical care for the poorest and
sickest Americans, and all state Medicaid
programs provide drug coverage for
most beneficiaries. 2 The wide gap in
access to prescription drugs between
non elderly Medicaid enrollees and
those with employer-sponsored coverage stands in contrast to other types
of care. For example, people with
Medicaid are more similar to those
with employer-sponsored coverage in
terms of unmet medical needs, having
a usual source of care and contact with
a physician in the past year.

Low Income, Poor Health
Compound Problems
Despite the assistance Medicaid
brings, beneficiaries' low incomes put
them at much higher risk of being
unable to afford prescription drugs.
Half of nonelderly adult Medicaid
beneficiaries have incomes below the
federal poverty level, or $8,590 for a
single person in 2001 (see Table 1);
three-quarters have incomes below
200 percent of poverty. By contrast,
only 3 percent of people with
employer-sponsored health coverage
have incomes below the poverty level,
while 14 percent have incomes below
200 percent of poverty.

Figure 1
Percent Not Obtaining Prescription Drug Due to Cost
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• Difference from elderly with Medicare is statistically significant at p<.OS level.
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Note: The categories of employer coverage, Medicaid roverage and the uninsured include adults ages 18-64.

Sou,.ce: Commumty Tracking Study Houselwld Survey, 2000-01

access problems
experienced by
Medicaid patients.

Web Exclusive ~
A more detailed
O~U~[.
analysis on this
topic can be found in
Research Report No.5,
"Affording Prescription
Drugs-Not Just a Problem
for the Elderly;' available
online at www.hschange.org.

Medicaid beneficiaries also tend to be in
poorer health. More than half of non elderly
adult beneficiaries are living with at least one
chronic condition, such as diabetes, heart
disease or depression, and more than one
in four has two or more such conditions.
In contrast, fewer than one-third of people
with employer-sponsored coverage have a
chronic condition, and only 10 percent have
two or more conditions.
Cost barriers are greater for people living
with chronic conditions across all categories
of insurance coverage (see Table 2). Especially
striking is the high proportion of Medicaid
beneficiaries and uninsured people with
chronic health conditions who report being
unable to afford prescription drugs. Perhaps
most troubling, more than 40 percent of
Medicaid patients with two or more chronic
conditions reported not obtaining prescription medications because of cost.
Thus, low incomes and high prevalence
of health problems put adult Medicaid beneficiaries at high risk for experiencing problems in affording prescription medications.
The study shows that these characteristics
largely explain the wide gap between

Medicaid and privately insured persons
when it comes to affording prescription
medications. But why has Medicaid-which
was designed to narrow this gap-failed in
this one critical aspect of care?

Cost Containment Linked to

Access Gaps
State efforts to control Medicaid prescription
drug spending appear to contribute to the
access problems experienced by Medicaid
patients. In the past few years, many states
have implemented a variety of methods to
control escalating Medicaid prescription
drug spending. These methods attempt to
control spending by influencing physicians'
prescribing patterns and patients' drug use.
Although methods vary from state to
state, the most common include imposing
nominal copayments, setting dispensing limits that restrict the number of prescriptions,
mandating substitution of generic drugs for
brand-name drugs, requiring prior authorization for certain drugs and issuing steptherapy protocols that require physicians to

Table 1
Health and Income Characteristics by Insurance Type (ages 18-64)

MEDICAID/OrHER
STATE CoVERAGE

UNINSURED

EMPLOYERSPONSORED
COVERAGE

PERCENT WITH INCOMFS
BELOW POVERTY

50%

26%

PERCENT WITH INCOMFS
BElWEEN 100% AND
200% OF POVElITY

25

30

11

23

14

20

29

6

10

PERCENT WITH
CONDITION*

3%

1 CHRONIC

PERCENT WITH 2 OR MORE
CHRONIC CONDITIONS*

" Conditions asked about in the su~y include diabetes, arthritis, asthma, chronic obstructive pulmonary disease, hype.rtension,
coronary heart disease, cancer, benign prostate disease, depression and other serious medicaJ problems that limit usual activities.
Note: Estimates reflect the percentage who responded "yes" to the following question: "During the past 12 months, was there
any time you needed prescription medicines bu t didn't get them because you couJdn't afford it?"

report cost barriers as those living in states
with either one or no cost-control policies
(see Figure 2).
States that implement multiple costcontrol methods may be much more
aggressive in trying to control Medicaid
prescription drug spending. Not only
would the cumulative effects of implementing these policies curtail access to a
greater degree than any single method, but
the individual methods themselves also
may be more stringent (e.g., higher copayments, stricter dispensing limits) in states
that are trying more aggressively to control
spending. While greater Medicaid savings
may be realized, an unintended consequence of aggressive cost-control policies
might be a reduction in beneficiary access
to needed prescription drugs.

Source: ('.,ommllnily Tracking Study Household SlIrvey, 2000-01

Policy Implications
Table 2
Percent Not Obtaining Prescription Drugs Due to Cost, by Insurance
Coverage and Chronic Condition Status for Nonelderly Adults (ages 18-64)
2 OR MORE

ALL PERSONS AGES 18-64

No CHRONIC

1 CHRONIC

CONDITIONS

CoNDITION *

10%

CHRONIC
CoNDITIONS*

17%**

25%**

EMPLOYER-SPONSORED
CoVERAGE

6

11**

15**

MEDICAID AND OTHER
STATE COVERAGE

16

26**

41**

UNINSURED

23

48**

61**

" Conditions asked about in the su~y indude diabetes, arthritis, asthma, chronic obstructive pulmonary disease, hypertension,
coronary heart disease, cancer, benign prostate disease, depression and other serious medicaJ problems that limit usual activities.

** Difference from persons with no chronic conditions is statistically significant at p< .05 level.
Note: Estimates reflect the percentage who responded "yes" to the following question: "During the past 12 months, was there
any time you needed prescription medicines but didn't get them because you couJdn't afford it?"

Source: Commllnity Tracking Study HOllsehold Survey, 2()()()-Ol

try lower-cost drugs before prescribing
more costlyalternatives.3
Individually, these cost controls do not
appear to significantly affect beneficiaries'
access to prescription drugs. Most states,
however, have implemented more than
one cost-control measure, and the study
shows that when multiple cost-control

measures are implemented, beneficiary
access to prescription drugs is affected to a
much greater extent (even after controlling
for beneficiary characteristics and other
community, state and regional factors).
For example, beneficiaries in states that
have implemented four or five cost-control
measures were about twice as likely to

o

While the recent policy debate has focused
on expanding prescription drug coverage
for senior citizens enrolled in Medicare,
the HSC study suggests that policy makers
should not ignore the difficulties many
non elderly patients face in affording drugs,
especially those who are uninsured or
enrolled in Medicaid.
The importance of prescription drugs
in medical care is growing as both the
number of people using prescription drugs
and the number of prescriptions per user
are increasing.4 Expenditures for prescription drugs now account for about 11 percent of personal health care expenses, up
from about 6 percent in 1988. 5 The importance and cost of prescription drugs in
medical care are likely to increase in the
future with the development of new drug
products, including those from the stillnascent biotechnology field. As drug products increase in both importance and cost,
policy makers will be confronted with the
challenge of making medications affordable and accessible to all Americans.
Many states currently are experiencing
Medicaid budget shortfalls, and state officials often point to rising Medicaid prescription drug spending as a major cause.
If these pressures continue or worsen, states
may become even more aggressive in their
efforts to control prescription drug expen-
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Figure 2
Summary of Effects of State Medicaid Cost-Control Methods on Beneficiaries'
Acc 55 to Prescription Drugs·
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Data Source
This Issue Brief presents findings
from the 2000-01 Community
Tracking Study Household
Survey, a nationally representative telephone survey of the
civilian, noninstitutionalized
population, supplemented by inperson interviews of households
without telephones to ensure
proper representation. The survey
contains observations on a total
of about 60,000 persons. The
sample for this study is based
on 39,000 adults ages 18-64,
including about 1,800 who are
in Medicaid or state coverage.
The response rate for the survey
was around 60 percent.
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* These methods include copayments, limits on the number of prescriptions, mandatory substitution of generics for brand-name
drugs, preauthorization requirements and step-therapy requirements.
Difference from persons in states that have implemented 0 or 1 requirement is statistically significant at p<.OS.

U

Estimates reflected regression-adjusted means that control for beneficiary characteristics and other community; state and regional
factors.
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Note: Sample includes persons ages 18-64 enrolled in Medicaid or state coverage programs.

Source: Community Tracking Study Household Survey, 2000-01
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ditures, further restricting beneficiary access.
White some may view these cost-control
methods as consistent with those used
by many private insurers, public officials
should keep in mind that the impact of
these methods on Medicaid beneficiaries
is likely to be greater given their higher
need and lower incomes. •
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THE COURT:

1

2

Good afternoon.

Be seated,

please.
In 2000 the Michigan Supreme Court, as we all

3
4

know, decided the case of Blank

5

Department of Corrections, 462 Michigan 103.

6

case the Department of Corrections r.ad promulgated a set

7

of rules without the approval of what was then known as

8

the joint committee on administrative rules, a:body

9

appointed by both houses of the legislature consisting

ve~sus

Michigan

In that

of members of the legislature.

10

The legislature had enacted in 1977 a statute,

11
12

Public Act 108, which required the approval of that

13

joint committee on administrative rules bafore any

14

executive agency could promulgate rules which 't'lould have

15

the force and effect of law.
A three-member plurality of the Michigan

16

17

Supreme Court was joined by a fourth

18

constituted a majority of the Supreme Court in holding

19

that the legislative veto over rules proposed by an

20

executive agency is inherently a legislative function

21

and is thus subject to the enactment and presencment

22

clauses of our state constitution, and ttis is true

23

whether the veto is exercised b~ the entire legislat~re

24

or something less thar. the entire

25

in

tha~

case, a
30t~

333

joi~c

me~be=,

which thus

legi91at~re,

suet as,

cc~mittee.

JUDICIAL

South Capitol Avent.:e

C:~CU:T

COU~T

S1J.::"te C Lar:9ing,
73

~I:

48933

1

The Supreme Court further held that the

2

statute in question delegated to that joint committee

3

authority to perform what the Supreme Court recognized

4

as essentially legislative acts and that the essence of

5

this was the committee's ability to, quote, exert a

6

policy-making effect equivalent to amending or repealing

7

existing legislation, close quote, and, quote,

8

therefore, such actions are subject to the

9

presentment requirements of our 1963 constitution, close

10

quote.

11

and page 119 of the Blank decision.

12

ena~tment

and

I'm quoting there from page 117, footnote eight,

Turning to the case before the Court today,

13

section 2204(1)

14

Health to submit proposed changes in its so-called

lS

pharmacies' policies for non-HMO Medicaid re=ipients and

16

certain others, to the chairs of the relevant senate and

17

house appropriations sub-committees.

19

unconstitutional about the requirement of submitting

19

that information.

20

chairs 30 days to veto any such changes in these

21

policies, and if those chairs do veto those policies,

22

those policies may r.o

23

req~i~es

the Department of Comnunity

There's nothing

Eut subsection three gives those

lo~ger

be executed.

This violates the Mic~igan constitution in

24

exactly the

2S

as 1977 Public Act lCB was declared to do so

sa~e man~e~

and for exactly the saxe reason
i~

the

30th JUDICIAL CIRCUIT CCURT
Suite C Lansing, MI 49933

333 South Capito: Avenue

76

1

Ela~k

case.
The Defendant argues that even if this

2
3

requirement is unconstitutional, it is moot because the

4

veto was r.ot exercised within 30 days and cannot now be

5

exercised.

6

committees did not disapprove of these changes does not

7

make the issue moot, in my opinion.

8

chairs, and in certain circumstances the

9

house leaders, to disapprove these changes must

But the fact that the chairs of the

The power of the
8enat~

and

10

necessarily have been taken into account in designing

11

the changes.

12

formal and informal communications which may have taken

13

place between these legislators and/or their staffs en

14

the one hand, and the people in the department who were

15

working on these policies on the other

16

presume that there were no such communications defies

17

common sense.

18

veto, it is clear that the wishes of the chairs, either

19

expressly communicated or inferred, would have to be

20

taken into account in designing the changes.

21

taints the entire plan and makes it an unconstitutior.al

22

exercise.

23

It is impossible to find out all of the

ha~d.

But to

In other words, once the chairs had the

This to me

In addition, I agree ·with the Plaintiffs that

24

the Defendant has failed to cite a:lY substantive

25

9~atutory a~~hority fo~ t~e

recovery of so-called
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~it~d

1

supplemental rebates.

No where has the Defendant

2

or quoted any federal or state statute which authorizes

3

a state agency to require a rebate in

4

beyond that expressly authorized in section

5

1396R(C) (1) (c) (i) of the Social Security Act.

6

that section of the Social Security Act merely

7

recognizes that states may, if properly authorized by

8

their legislatures, create their own programs

9

federal programs -- which result in lower prescription

to or

additio~

To me

~-

not

10

drug prices.

However, the section of the federal act

11

which has been cited by the Defendant does not and

12

cannot

13

by the respective state legislatures

14

enacced state statutes.

15

the authority to require supplemental rebates.

autho~ize

16

states to do so.

This can only be done
throug~

duly

So the department does not have

I agree with the Defendant that the so-called

17

veto provisions of section 2204(3) would be severable

18

under the tests laid out in MeL 8.5.

19

although it is invalid, the rest of the

20

permeated with it.

21

is my view that once this veto was granted, it must

22

necessarily have

23

taking into account the actual

24

c~airs

2S

the

stat~te

is not

However, as I have said earlier, it

res~lted

of tr.e respective

e~tire

That is to say,

-

in the executive
~r

depart~ent

presumed views of the

s~b-committees,

and ttis

exercise.
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tai~ts

Now, as to the granting of an injunction.

1

I

2

have said this morning that time constraints have not

3

allowed the Court to hear the separate

4

Intervening Plaintiffs for preliminary injunction.

5

However, I believe that I may take judicial

6

least some of the Intervening Plaintiffs' r.eeds and

7

characteristics.

mot~on

of the

~otice

of at

It is indisputable that disadvantage4 persons

8

9

who are in need of continuing medical services which

10

involve prescription drugs will be affected by these

11

programs.

12

technician and then to a pharmacist and then to a

13

physician, only during business hours, will undoubtedly

14

result in delays in the dispensing of the medications

15

which physicians judge to be medically

16

this is putting the best face on it as described by

17

counsel for the

18

irreparable harm to those patients who

19

affected.

The system of telephone appeals to a

Defe~dants.

~ecessar/,

and

To me this constitutes
w~uld

be so

I have not ruled that preapproval per se is

20
21

unlawful or unconstitutional.

22

authorized by the appro?riations act.

23

take into accot:.nt realistic expe'c tations as to t~e

24

effects

25

whether the uncons=itutional provisior.s

t~e p~eapprcval
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1

necessary under the applicable standards for me to grant

2

the injunction.
The

3

patie~t9

will be dramatically and

4

immediately affected in their personal health.

The

5

to the state will be monetary.

6

prospective harms favors the Intervening

7

saying this, I do not in any sense intend to make light

8

of what I believe we all know is a very

9

and budgetary situation for the state

ha~m

Thus, the balance of
~laintiffs.

seriou~

In

fiscal

governmen~,

but

10

under my view of the constitutional and statutory

11

issues, I believe that the Plaintiffs are much more

12

harmed in this case, and that is to say, the Intervening

13

Pla~ntiff9,

14

to prevail for the reasons I have already stated.

15

under the standards which I must follow, the

16

must issue, and I will issue it.

than the Defendant, and they are most likely

Thus,

injunctio~

I will ask that the attorneys for the

17
18

Plaintiffs get together and draft an appropriate

19

injunction with approval as to form by the Defendants,

20

not to be unreasonably withheld.

21

MS. MARSDEN:

Your

22

would like to make an oral

23

preliminary

24

Cc~rt

25

~nj~ction

Ho~or,

motio~

at this time we

for a stay of

~he

pendir.g "emergency appeal to the

of Appeals.
THE COURT:

Response?
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MR. MARSAC:

1

We oppose that, Your Honor.

I

2

think what the State is asking for is that they be

3

allowed to proceed with what the Court has already

4

determined to be an unconstitutional format.

5

stay the proceedings at this point -- to stay the

6

issuance of the injunction would allow them to proceed

7

and engage in conduct that would render irreparable

8

injury to the parties, and I think it would be_totally

9

inappropriate under the circumstances.

10

undermined the Court's order.

11

MR. CODY:

12

THE COURT:

13

It would

We would join in that, Your Eonor.
You may seek a stay from the Court

MS. MARSDEN:

Your Honor, I have prepared a

15

proposed order denying stay.

16

signature?
THE COURT:

17

Yes.

May r present it for your

Also seek approva2 as to

form.
MS. MARSDEN:

20

think to

of Appeals along with your emergency appeal.

14

18

I

Yes.

r want you also all to get

THE COURT:

21

together this afternoon and try to get an injunction

22

batted out that I can sigr. ft so that is not a barrier

23

to the State's ability to pursue this appeal.
MARSDEN:

24

~S.

25

THE COURT:

30th
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1

may have to consider an emergency motion tomorrow

2

afternoon.

3

that I've made the correct decision, I don't want to do

4

anything to hobble the State's ability to see if the

5

Court of Appeals, and ultimately the Supreme Court, may

6

disagree.

In other words, although I obviously feel

7

MS. MARSDEN:

8

THE COURT:

9

Your Honor
No dispute as to form on_this

order of denying motion for stay?

10

MR. MARSAC:

I don't believe so, Your Honor.

11

THE COURT:

12

MR. CODY:

13

MS. MARSDEN:

All right.

None, Your Honor.
Your Honor, if I might suggest

14

now, and this, perhaps, would simplify matters, I would

15

not be opposed to an order saying that the injunction is

16

issued for the reasons stated by the Court, and then we

17

don't have a problem agreeing to the verbiage, and we'll

18

get a copy of the transcript.

19

easiest way.

20

MR.

Your Honor, we have an o=der that

~~SAC:

21

we had attached to our motion.

22

take a quick review of that

23

it's acceptable.

24

THE COURT:

25

see if you can ag=ee
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1

chambers in the foreseeable future.

If you cannot

2

agree, then r as I say, tomorrow you can seek emergency

3

relief some time late in the morning, early afternoon.
I will give you back this order denying the

4

5

motion to stay, which I've signed.

6

court file in my office.

7

downstairs on the first floor will be happy to take

8

this.

10

THE COURT:

11

MR. MARSAC:

12

No, here it is.

The clerks

-Thank you very much.

MS. MARSDEN:

9

I think I have the

Anything else?
That's all.

We'll work on the

order.
Thank you.

13

THE COURT:

14

(Whereupon hearing concluded at 3:16 p.m.)
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CURRENT 2003 BUDGET LANGUAGE
Page 49
14

Sec 1627. (1) The department shall use provisions specified under
Section 1927 of title XIX of the social security act, 42 U.S.C. 1396r-8, to secure
quarterly rebates from pharnlaceutical manufacturers for drugs dispensed to
participants in state-funded programs.

19

2) for products distributed by pharmaceutical manufacturers not providing
quarterly rebates as listed in subsection (1), the department may require
preauthorization for prescriptions dispensed to participants in state-funded
programs.

AMEND SEC. 1627 OF THE 2003 BUDGET BILL TO READ AS FOLLOWS:
Sec. 16287. (1) The department may negotiate with pharmaceutical
manufacturers to obtain the same level of quarterly rebates as specified
under Section 1927 of title XIX of the social security act, 42 U.S.C. 1396r-8
for drugs dispensed to Medicaid recipients enrolled in managed care plans
and to participants in the following state-funded programs: Elderly
P,r escription Insurance Coverage Program (EPIC), MI Family, Children
With Special Health Care Needs, Wayne County Pluscare and MI
Department of Corrections.
2) Products of pharmaceutical manufacturers that provide quarterly
rebates pursuant to subsection (1), shall be made available in the Medicaid
program and to the participants in the programs listed in subsection (1)
without prior authorization or other restrictions.
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SENATE BILL No. 1101 February 13, 2002, Introduced by Senators Gougeon, Schwarz, Johnson and Smith and
referred to the Committee on Appropriations.

EXECUTIVE BUDGET BILL

A bill to make appropriations for the department of community

,....
o
,....
,....
.
o

public health, and medical services for the fiscal year ending

..J

appropriations; to create funds;

health and certain state purposes related to aging, mental health,

September 30, 2003; to provide for the expenditure of such

Z

to provide for reports;

to

--Ir:D

prescribe the powers and duties of certain local and state

W

agencies and departments; and to provide for disposition of fees

....
«
z

and other income received by the various- state agencies.
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1

(2) When carved-out of the capitation rate for managed care

2 recipients, the pharmaceutical dispensing fee shall be $3.77 or
3 the pharmacy's usual or customary cash charge or the usual charge
4 allowed by the recipients's medicaid HMO, whichever is less.
5

(3) The department shall require a prescription copayment for

6 medicaid recipients except as prohibited by federal or state law
7 or regulation.
8

Sec. 1624. An additional $20,000,000.00 in tobacco settlement

9 funds are hereby appropriated to the elder prescription insurance
10 coverage program if the state budget director certifies that the
11 federal funds appropriated to that program are unavailable and
12 that sufficient tobacco settlement revenue is available to finance
13 this appropriation.
14

Sec. 1627.

(1) The department shall use provisions specified

15 under section 1927 of title XIX of the social security act,
16

42

u.s.c. 1396r-8, to secure quarterly rebates from pharmaceutical

17 manufacturers for outpatient drugs dispensed to participants in
18 state-funded programs.
19

2) For products distributed by pharmaceutical manufacturers

20 not providing quarterly rebates as listed in subsection

(1),

the

21 department may require preauthorization for prescriptions
22 dispensed to participants in state-funded programs.
23

Sec. 1631. The department shall require copayments on dental,

24 podiatric,

chiropractic, vision, and hearing aid services provided

25 to Medicaid recipients, except as prohibited by federal or state
26 law or regulation.
27

Sec. 1641. An institutional provider that is required to

28 submit a cost report under the medical services program shall

06627'02

SB 1101, As Passed Senate, March 20, 2002
Senate Bill No. 1101

75

1

Medicaid, unless subsequent consultation with the prescribing physician

2

indicates otherwise.

3

Sec. 1624.

(1) An additional $20,000,000.00 from the tobacco set-

4

tlement trust fund is appropriated to the elder prescription insurance

5

coverage program for fiscal year 2002-2003 if the state budget director

6

certifies that the federal funds appropriated to that program are

7

unavailable and that sufficient tobacco settlement revenue is available

8

to finance this appropriation.

9

ment revenue" and "tobacco settlement trust fund" mean those terms as

As used in this section, "tobacco settle-

10

defined in section 2 of the Michigan trust fund act, 2000

11

MCL 12.252.

12

P~489,

(2) None of the tobacco settlement or other state restricted revenue

13

appropriated by the department to the EPIC program in fiscal year

14

2001-2002 shall lapse.

15

(3) The department shall place any funds that would have lapsed in a

16

reserve account for the sole purpose of providing revenue to fund the

17

EPIC program during fiscal year 2002-2003, in

18

eral revenue to enhance EPIC program funding is not available.

19

(4)

t~e

event the proposed fed-

If the proposed federal funds become available, the reserved

20

tobacco settlement funds may either be lapsed to the tobacco settlement

21

trust fund or the Medicaid trust fund.

22

Sec. 1627.

(1) The department may negotiate with pharmaceutical

23

manufacturers to obtain the same level of quarterly rebates described in

24

section 1927 of title XIX, 42 U.S.C. 1396r-8, for drugs dispensed to

25

Medicaid recipients enrolled in managed care plans and to participants in

26

the eligible programs.

506627'02
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(2) The program described in subsection (1) shall meet all of the
.following:
(a) The rebates shall be payable for drugs dispensed to Medicaid

4

recipients enrolled in managed care plans only upon written confirmation

5

by the United States secretary of health and human services that the

6

rebates are not included in computing the manufacturer's best price as

7

defined in section 1927(c) (1) (C) of title XIX, 42 U.S.C. 1396r-8.

8
9

(b) The rebates shall be payable for drugs dispensed to participants
in each of the eligible programs only upon written confirmation by the

10

United States secretary of health and human services that the rebates

11

paid for each eligible program are not included in computing the

12

manufacturer's best price as defined in section 1927 (c) (1) (C) of title

13

XIX, 42 U.S.C. 1396r-8.

14

(c) The per unit rebate amount reported by each participating phar-

15

maceutical manufacturer to the state for purposes of this section shall

16

be maintained in confidence and used only for purposes of administering

17

this program, and shall not be disclosed in a

18

or indirectly the rebate amount for a specific drug or rebates payable by

19

a pharmaceutical manufacturer.

20

f~rm

that reveals directly

(3) Pharmaceutical manufacturers that provide quarterly rebates pur-

21

suant to subsection (1) for all of their products dispensed for all par-

22

ticipants in all eligible programs shall have all of their products made

23

available without prior authorization or other restrictions in the

24

Medicaid program, except for those drugs for which the department

25

required prior authorization during fiscal year 2000-2001 and except for

26

those drugs dispensed to Medicaid recipients enrolled in health plans.

S06627'02 (S-l)

SB 1101, As Passed Senate, March 20, 2002
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1
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(4) As used in this section, "eligible programs" means the following

2

~rograms

3

program, MIFamily or its predecessor programs, children's special health

4

care services, Wayne County pluscare, and any medical care program oper-

5

ated by the department of corrections or another state facility.

6

funded by this state:

Sec. 1628.

the elder prescription insurance coverage

It is the intent of the legislature that if the savings

7

for Medicaid pharmacy rebates .exceed the amount budgeted in this act, the

8

savings shall first be used to offset any increase in pharmacy costs

9

above that budgeted in this act and then to support and expand coverage

10
11

under the EPIC program.
Sec. 1630.

Medicaid adult dental services, podiatric services, and

12

chiropractic services shall continue at not less than the level in effect

13

on October 1, 1996, except that reasonable utilization limitations may be

14

adopted in order to prevent excess utilization.

15

impose utilization restrictions on chiropractic services unless a recipi-

16

ent has exceeded 18 office visits within 1 year.

17

Sec. 1631.

The department shall not

The department shall require copayrnents on dental, podi-

18

atric, chiropractic, vision, and hearing aid services provided to

19

Medicaid recipients, except as prohibited by federal or state law or

20

regulation.

21

Sec. 1633.

From the funds appropriated in part 1 for auxiliary med-

22

ical services, the department shall expand the healthy kids dental pro-

23

gram statewide if funds become available specifically for expansion of

24

the program.

25

26

Sec. 1634.

(1) From the funds appropriated in part 1 for ambulance

services, the department shall continue the 5% increase in payment rates

S06627'02 (S-l)

Corporate Mfairs
Pfizer Inc
209 North Walnut, Suite C
Lansing, MI 48933
Tel 517 485 8301 Fax 517 485 8525
Email hill.howe@pfizer.com

c.

William Howe

Manager
State Government Relations

llpUl 8, 2002

9)1(,,, 9)cwid

g andtJ

9)iw:Uvt, ~

ScJlw.taM ff~
1101 .MceJung g~ and fffwza
:JCmvxviIle, g.N 37996

gP,e pwtp~e oj tit.i6 feu~. i6 w. plt.ottitk LJ.(JU willi nul a66e66ment oj . ,"",,,
!JlmuuJt :JWeJt'" p~ dwdtuj Pwt ~Ptip willi ff{ilzeJt'" ~
19f1ke oj StaU ~ 9lelatiOlM. J abo. wmd to. tafu tIW o.ppOJtltutitlJ to.
ea;pU6" ttUJ "inuJte, appuciation to. tpm and tfte otIteJt ~ 01 tfte ~
ScJlw.taM SenUvt ffwJut &unmittee /oJt tpUVt ~" to. ~UWt and
uitimateltJ appuw.e ~" :JWeJt'" pwdicipalUm in tfte :f{iIzeJt J nl:eJtn6Ptip
p~ fJuun Jmuuvui 2, 2002 tIVuuuJfi ap'til19, 2002"

J n tfte ~ tulmiiWl!tatitte p0-6i.tUJ.n6 tfud J fuw.e occupied witIiin tfte pul1f.k
and pUvak ,,~ dwdtuj tIie p~t tf1WthJ ~, J fuw.e Puul tIie oppOJtltutitlJ to.
"upew.i6e (W.eJt "ia:bJ ~ and can "taU, witIuud ~itation, tfud ~" :JWe't i6
tfte I1Ul6t 1'~"Uuud and U61'006iM£ inWtn J fuw.e ~ fuul tfte 0I'1'CJ.Jdunifg
to. "upew.i6e.. ~. Pwt ~ I'~ i6 a l!tiDuh to. Pwt6eJt. tpUVt
indio.idual educati.onal e/f&d4 and tlie ~ibJ oj g emte66U"

g (J. tire eat.ent pru6iftf.e., J end.eatf.(JJt t.fJ. allow. an· inWtn w. 6.ec.ome a pwtt of tire
team efIwd widiin tire o.fIice to. acaunpfi6/i 0Wi a66igned ta6~ and
'te6p~i8i~. J atWnpt to. a66ig.n inWtn 'te6p~i8i~ ~wud.e, witIi
tire inWtn'6 ~, peJt6cmalittj and WOJtft edtic to. PWltide tItem witIi tire k6t
ea:peJtimce P(J.66ifJL In tfW ~, J,(, .. 3WeIi'6 wmpfethm 4 a nunriJe,t, 4
~e and difIkult ta6~ fZuu, 6een fltttllJ imp'te66We.

J

~

M6 . 3WeIi fZuu, gaitred 6ifJni1icmd fmowledge 4 tire CJtiucal 6u6ine66

i661U6 impacting tire pPuvurureelitical indu.6l!uJ, tire ~ ~ witIi
impacting puMic poliaJ ~otreO tI'vuuuJIt ~laLWn and tPte diIfia'lUj "" wJl
a6 tire impOJdance 4 6uildituj and maintainituJ ~61UUJ.f6 ulaU6n6/iip6 .

llltIuuupi IJOU wte auJ.Wte, 4 M6. :Jli6e1i'6 adioitie6 tI'vuuuJIt fwt 6u1uni66Um 4
W€dUlJ· 'l.ep~, J tIiin& it lOO1dIuJ of 'l.eiWuding. tlie. ~ignificanc.e. 4 wfrat ..4t6 .
:Jli6e1i ~ acaunpfi6lied:
Jniliated cmrfud and devJoped ~/iip6 witIi ~ IiealtIi
a66(J~ and 6enUJJi cenWt 'tefJ'te6entatW.e6 in :i)ebtoit, q,uuut 9lapid6
and ~ituj wt£a6 in an efIwd to. 6.uild a ~61UUJ.f6 audition to. impact
puMic poliaJ ~laLWn
• (L,6i6ted witIi tire ~ and pftuuting 4 a nre.etiIuJ 4 (J.(Wt, 3{)
_
ccmceJtnin.g JJtWicaid/JKedicmte ufated i661U6 .
• [Juwided 6ifJni1icmd ~ to. [Jfi.ze!t'6 team efIwd to. devJop
pO-UWi-pcUnt p~~ peJdainin.g te. tfre !}fi.ze!t SfUvte &vtd
p~CJtiptUm medicatUm puuptatn and tire adv.eJt6e impact 4 tire
Medicaid !J'te6CJtiptUm:i>wg ~~pttitvt, ~" pcJicre6
• &mrp&ted ~ p~oUuud, ~ and e/I«li(le;
p'te6~ to. a v.wtidtJ 4 ~ ccmceJtnin.g !Jfi.ze!t'o SfUvte &vtd
p'te6CJtiptUm nredicatum puuptatn and tire adv.eJt6e impact 4 tire
Medicaid ff'te6CJtiptUm :i)wg ~~ pltUvi ~" pcJicre6
•

• Witii limited fJuidance, 6~6fulbJ 60ficited tPte pwdicipatitm oj
~ v.oluntwuJ IiealtIi and 6enUJJt, cenWt _
to. 6eJtOO "" tPte
9Jcuvtd 4 !i)~ fwt tPte s~ /tvt fY~CJtiption !i)'UUj f}~6
~alition

4

~
tfre fYW6CJtiptUm !i)'""I f}~6 ~alilion
facifiUdiIUj email and ~ call ~,

• SeJWd"" tPte

t/vuuu;JJi

- pupwtinfJ ~ fwt 9Jcuvtd ~, 6eavtiIuJ tfre ~6WUJ 6mUi
do.aunent6 and 6eJUJing "" an ongoing ~ W6CUtJtCe fwt
~ali.tUm~

•

f}unctUmed"" a p'tinuvuJ amlad joJt inWuud fY/ize!t p~CJIltlel and
cmMtdtant ~ engaged in an efIwd to. ~ tfre pufdk pJia;
i,66ue ~ to. tfre .Mulicaid tt pWvi ~" pW-f}'tCUn t/vuuu;JJi

tfre ¥latWe

p'UJ.Ce66

lldditio.n.a.l4,

jtt,.. ~e.'t'6 ckdication, ea:ceptWnal analytical t.alenk ,
p~6Uuud and ~1Je CJJUd and WJtitWt ~ 6fdlb and aptitude
fwt q.uicIdlJ ",,6itnilalitu; 6a/ient i,66ue6 fJuun 6ignifk,ant ClI1UUUll6 4 dnta au
u.eJUJ imp'l£66w.e.. a u.eJUJ intJligmt indioidual w.itJi ~ pwMem ,,~
a8iliti~ wIUdi, cMnlUned w.itJi tiel{, comp",,6Umat.e u~tandUuJ· oj ~, Ita6
6un a ~ ",,6et to. fY/ize!t clwtituj /iett inteJtn61iip .

51ian/i IJ6U fwt tfre oppOJdunittj to. fuwe ~.. :-JWe't pwdicipate in owt fI /ize!t
inteJtn6/iip pW-f}'tCUn, "" 6Pte ceJttainllj i,6 a ~ IJ6WUI woman wIuJ.
pM6e66e6 6fdlb and ~ 6apmd fwt, tpaJi" ..

S~,

.•

c.~~

'sa

e. WiHUun JbJwe,
~

State ~ !ll.efuti0n6

Works Cited

Cunningham, Peter J. "Prescription Drug Access: Not Just A Medicare Problem." Center for
StudyingBealth System Change April 2002 <http://www.hschange.org/CONTENT/429>.
Durbin, Dee-Ann. "Senior Groups Square Off Over Medicaid Prescription Program." A£
Newswires 12 Mar. 2002:
Gold, Russell, Scott Hensley, and Andrew Caffrey. "States Square Off Against Drug Firms in
Crusade on Prices; Michigan's New Experiment Leads Pfizer and Others To Stage a Boycott."
New York Times 7 Dec. 2001: AI.
Gold, Russell. "Injunction Blocks Michigan Medicine Law." Wall Street Journal 8 Jan. 2002:
A4.
Pear, Robert. "Many on Medicaid Lack Drugs, Study Says." New York Times 9 Apr. 2002: A22.
Soumerai, Stephen B., "Effects of Medicaid Drug-Payment Limits on Admission to Hospitals
and Nursing Homes." The New England Journal of Medicine 325 (1991): 1072-1077.

